<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Phosphoinositide 3-kinase</title><meta name="description" content="Phosphoinositide 3-kinases (PI3Ks), also called phosphatidylinositol 3-kinases, are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. PI3Ks are a family of related intracellular signal transducer enzymes capable of phosphorylating the 3 position hydroxyl group of the inositol ring of phosphatidylinositol (PtdIns). The pathway, with oncogene PIK3CA and..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="PI3K, Phosphatidylinositol 3-kinase, PI 3-kinase, PI3-kinase"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Phosphoinositide_3-kinase"/><meta property="og:title" content="Phosphoinositide 3-kinase"/><meta property="og:description" content="Phosphoinositide 3-kinases (PI3Ks), also called phosphatidylinositol 3-kinases, are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. PI3Ks are a family of related intracellular signal transducer enzymes capable of phosphorylating the 3 position hydroxyl group of the inositol ring of phosphatidylinositol (PtdIns). The pathway, with oncogene PIK3CA and..."/><meta property="og:url" content="https://grokipedia.com/page/Phosphoinositide_3-kinase"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Phosphoinositide 3-kinase"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:13.160Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Phosphoinositide 3-kinase"/><meta name="twitter:description" content="Phosphoinositide 3-kinases (PI3Ks), also called phosphatidylinositol 3-kinases, are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. PI3Ks are a family of related intracellular signal transducer enzymes capable of phosphorylating the 3 position hydroxyl group of the inositol ring of phosphatidylinositol (PtdIns). The pathway, with oncogene PIK3CA and..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="6fc78d152511af0fec6fc34d4584cf19-bb999b61fa7997ae-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=6fc78d152511af0fec6fc34d4584cf19,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.9862469833205274,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#phosphoinositide-3-kinase" class="transition-opacity hover:opacity-100 opacity-50">Phosphoinositide 3-kinase</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#discovery" class="transition-opacity hover:opacity-100 opacity-50">Discovery</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#classes" class="transition-opacity hover:opacity-100 opacity-50">Classes</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#class-i" class="transition-opacity hover:opacity-100 opacity-50">Class I</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#classes-ii-and-iii" class="transition-opacity hover:opacity-100 opacity-50">Classes II and III</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#class-iv" class="transition-opacity hover:opacity-100 opacity-50">Class IV</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#human-genes" class="transition-opacity hover:opacity-100 opacity-50">Human genes</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#mechanism" class="transition-opacity hover:opacity-100 opacity-50">Mechanism</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#phosphoinositide-3-kinases" class="transition-opacity hover:opacity-100 opacity-50">Phosphoinositide 3-kinases</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#function" class="transition-opacity hover:opacity-100 opacity-50">Function</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#mechanism-1" class="transition-opacity hover:opacity-100 opacity-50">Mechanism</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#cancers" class="transition-opacity hover:opacity-100 opacity-50">Cancers</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#learning-and-memory" class="transition-opacity hover:opacity-100 opacity-50">Learning and memory</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pi-3-kinases-as-protein-kinases" class="transition-opacity hover:opacity-100 opacity-50">PI 3-kinases as protein kinases</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#inhibition" class="transition-opacity hover:opacity-100 opacity-50">Inhibition</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pi3k-inhibitors-as-therapeutics" class="transition-opacity hover:opacity-100 opacity-50">PI3K inhibitors as therapeutics</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="phosphoinositide-3-kinase" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Phosphoinositide 3-kinase<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Phosphoinositide 3-kinases</strong> (<strong>PI3Ks</strong>), also called <strong>phosphatidylinositol 3-kinases</strong>, are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer.</span>
<span class="mb-4 block break-words text-[1em] leading-7">PI3Ks are a family of related intracellular signal transducer enzymes capable of phosphorylating the 3 position hydroxyl group of the inositol ring of phosphatidylinositol (PtdIns).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_21abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> The pathway, with oncogene PIK3CA and tumor suppressor gene PTEN, is implicated in the sensitivity of cancer tumors to insulin and IGF1, and in calorie restriction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_41abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<h2 id="discovery" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Discovery<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The discovery of PI3Ks by <span class="inline text-[1em] leading-7">Lewis Cantley</span> and colleagues began with their identification of a previously unknown phosphoinositide kinase associated with the <span class="inline text-[1em] leading-7">polyoma</span> middle T protein.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_62abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> They observed unique substrate specificity and chromatographic properties of the products of the lipid kinase, leading to the discovery that this phosphoinositide kinase had the unprecedented ability to phosphorylate phosphoinositides on the 3&#x27; position of the inositol ring.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_82abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Subsequently, Cantley and colleagues demonstrated that <em>in vivo</em> the enzyme prefers PtdIns(4,5)P2 as a substrate, producing the novel phosphoinositide <span class="inline text-[1em] leading-7">PtdIns(3,4,5)P3</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> previously identified in neutrophils.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<h1 id="classes" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Classes<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">The PI3K family is divided into four different classes: <span class="inline text-[1em] leading-7">Class I</span>, <span class="inline text-[1em] leading-7">Class II</span>, <span class="inline text-[1em] leading-7">Class III</span>, and Class IV. The classifications are based on primary structure, regulation, and <em>in vitro</em> lipid substrate specificity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<h3 id="class-i" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Class I<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Class I PI3Ks catalyze the conversion of <span class="inline text-[1em] leading-7">phosphatidylinositol (4,5)-bisphosphate</span> (PI(4,5)P2) into <span class="inline text-[1em] leading-7">phosphatidylinositol (3,4,5)-trisphosphate</span> (PI(3,4,5)P3) <em>in vivo</em>. While <em>in vitro</em>, they have also been shown to convert <span class="inline text-[1em] leading-7">phosphatidylinositol</span> (PI) into <span class="inline text-[1em] leading-7">phosphatidylinositol 3-phosphate</span> (PI3P) and <span class="inline text-[1em] leading-7">phosphatidylinositol 4-phosphate</span> (PI4P) into <span class="inline text-[1em] leading-7">phosphatidylinositol (3,4)-bisphosphate</span> (PI(3,4)P2), these reactions are strongly disfavoured <em>in vivo</em>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_n4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> The PI3K is activated by <span class="inline text-[1em] leading-7">G protein-coupled receptors</span> and <span class="inline text-[1em] leading-7">tyrosine kinase receptors</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_t4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Class I PI3Ks are <span class="inline text-[1em] leading-7">heterodimeric</span> molecules composed of a regulatory and a catalytic <span class="inline text-[1em] leading-7">subunit</span>; they are further divided between IA and IB subsets on sequence similarity. <strong>Class IA PI3Ks</strong> are composed of a heterodimer between a p110 catalytic subunit and a shorter regulatory subunit (often p85).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_84qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> There are five variants of the regulatory subunit: the three <span class="inline text-[1em] leading-7">splice variants p85Î±, p55Î±, and p50Î±</span>, <span class="inline text-[1em] leading-7">p85Î²</span>, and <span class="inline text-[1em] leading-7">p55Î³</span>. There are also three variants of the p110 catalytic subunit designated p110Î±, Î², or Î´ catalytic subunit. The first three regulatory subunits are all splice variants of the same gene (<em>Pik3r1</em>), the other two being expressed by other genes (Pik3r2 and Pik3r3, p85Î², and p55Î³, respectively). The most highly expressed regulatory subunit is p85Î±; all three catalytic subunits are expressed by separate genes (<em>Pik3ca</em> , <em>Pik3cb</em> , and <em>Pik3cd</em> for <span class="inline text-[1em] leading-7">p110Î±</span>, <span class="inline text-[1em] leading-7">p110Î²</span>, and <span class="inline text-[1em] leading-7">p110Î´</span>, respectively). The first two p110 isoforms (Î± and Î²) are expressed in all cells, but p110Î´ is expressed primarily in <span class="inline text-[1em] leading-7">leukocytes</span>, and it has been suggested that it evolved in parallel with the adaptive immune system. The regulatory p101 and catalytic <span class="inline text-[1em] leading-7">p110Î³</span> subunits comprise the <strong>class IB PI3Ks</strong> and are encoded by a single gene each (<em>Pik3cg</em> for <span class="inline text-[1em] leading-7">p110Î³</span> and <em>Pik3r5</em> for p101).</span>
<span class="mb-4 block break-words text-[1em] leading-7">The p85 subunits contain <span class="inline text-[1em] leading-7">SH2</span> and <span class="inline text-[1em] leading-7">SH3</span> domains (<span class="inline text-[1em] leading-7">Online Mendelian Inheritance in Man</span> (OMIM): <a href="https://omim.org/entry/171833" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">171833</a>). The SH2 domains bind preferentially to phosphorylated tyrosine residues in the amino acid sequence context Y-X-X-M.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup></span>
<h3 id="classes-ii-and-iii" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Classes II and III<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Class II</span> and <span class="inline text-[1em] leading-7">III</span> PI3Ks are differentiated from the Class I by their structure and function. The distinct feature of Class II PI3Ks is the C-terminal C2 domain. This domain lacks critical <span class="inline text-[1em] leading-7">Asp</span> residues to coordinate binding of Ca2+, which suggests class II PI3Ks bind lipids in a Ca2+-independent manner.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Class II comprises three catalytic isoforms (C2Î±, C2Î², and C2Î³), but, unlike Classes I and III, no regulatory proteins. Class II catalyse the production of PI(3)P from PI and PI(3,4)P2 from PI(4)P; however, little is known about their role in immune cells. PI(3,4)P2 has, however, been shown to play a role in the invagination phase of clathrin-mediated endocytosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_26qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> C2Î± and C2Î² are expressed through the body, but expression of C2Î³ is limited to <span class="inline text-[1em] leading-7">hepatocytes</span>.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Class III PI3Ks produce only PI(3)P from PI <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_27abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> but are more similar to Class I in structure, as they exist as heterodimers of a catalytic (<span class="inline text-[1em] leading-7">Vps34</span>) and a regulatory (Vps15/p150) subunits. Class III seems to be primarily involved in the trafficking of proteins and vesicles. There is, however, evidence to show that they are able to contribute to the effectiveness of several process important to immune cells, not least <span class="inline text-[1em] leading-7">phagocytosis</span>.</span>
<h3 id="class-iv" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Class IV<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">A group of more distantly related enzymes is sometimes referred to as class IV PI3Ks. It is composed of <span class="inline text-[1em] leading-7">ataxia telangiectasia mutated</span> (ATM), <span class="inline text-[1em] leading-7">ataxia telangiectasia and Rad3 related</span> (ATR), DNA-dependent protein kinase (DNA-PK) and <span class="inline text-[1em] leading-7">mammalian target of rapamycin</span> (mTOR). They are protein serine/threonine kinases.</span>
<h1 id="human-genes" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Human genes<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>














































































































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">group</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">gene</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">protein</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">aliases</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">EC number</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">class 1 catalytic</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">[PIK3CA]</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">PI3K, catalytic, alpha polypeptide</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">p110-Î±</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">[2.7.1.153]</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">[PIK3CB]</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">PI3K, catalytic, beta polypeptide</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">p110-Î²</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">[2.7.1.153]</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">[PIK3CG]</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">PI3K, catalytic, gamma polypeptide</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">p110-Î³</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">[2.7.1.153]</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">[PIK3CD]</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">PI3K, catalytic, delta polypeptide</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">p110-Î´</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">[2.7.1.153]</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">class 1 regulatory</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">[PIK3R1]</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">PI3K, regulatory subunit 1 (alpha)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">p85-Î±, p55-Î±, p50-Î± (splice variants)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">N/A</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">[PIK3R2]</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">PI3K, regulatory subunit 2 (beta)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">p85-Î²</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">N/A</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">[PIK3R3]</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">PI3K, regulatory subunit 3 (gamma)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">p55-Î³</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">N/A</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">[PIK3R4]</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">PI3K, regulatory subunit 4</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">p150</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">N/A</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">[PIK3R5]</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">PI3K, regulatory subunit 5</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">p101</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">N/A</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">PIK3R6</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">PI3K, regulatory subunit 6</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">p87</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">N/A</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">class 2</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">[PIK3C2A]</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">PI3K, class 2, alpha polypeptide</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">PI3K-C2Î±</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">[2.7.1.154]</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">[PIK3C2B]</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">PI3K, class 2, beta polypeptide</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">PI3K-C2Î²</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">[2.7.1.154]</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">[PIK3C2G]</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">PI3K, class 2, gamma polypeptide</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">PI3K-C2Î³</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">[2.7.1.154]</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">class 3</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">[PIK3C3]</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">PI3K, class 3</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Vps34</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">[2.7.1.137]</span></td></tr></tbody></table></div>
<h2 id="mechanism" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Mechanism<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The various 3-phosphorylated <span class="inline text-[1em] leading-7">phosphoinositides</span> that are produced by PI3Ks (<span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">t</mi><mi mathvariant="normal">d</mi><mi mathvariant="normal">I</mi><mi mathvariant="normal">n</mi><mi mathvariant="normal">s</mi><mn>3</mn><mi mathvariant="normal">P</mi></mrow><annotation encoding="application/x-tex">\mathrm{PtdIns3P}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height:0.6944em"></span><span class="mord"><span class="mord mathrm">PtdIns3P</span></span></span></span></span>, <span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">t</mi><mi mathvariant="normal">d</mi><mi mathvariant="normal">I</mi><mi mathvariant="normal">n</mi><mi mathvariant="normal">s</mi></mrow><mo stretchy="false">(</mo><mn>3</mn><mo separator="true">,</mo><mn>4</mn><mo stretchy="false">)</mo><msub><mi>P</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PtdIns}(3,4)P_2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height:1em;vertical-align:-0.25em"></span><span class="mord"><span class="mord mathrm">PtdIns</span></span><span class="mopen">(</span><span class="mord">3</span><span class="mpunct">,</span><span class="mspace" style="margin-right:0.1667em"></span><span class="mord">4</span><span class="mclose">)</span><span class="mord"><span class="mord mathnormal" style="margin-right:0.13889em">P</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height:0.3011em"><span style="top:-2.55em;margin-left:-0.1389em;margin-right:0.05em"><span class="pstrut" style="height:2.7em"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">2</span></span></span></span><span class="vlist-s">â€‹</span></span><span class="vlist-r"><span class="vlist" style="height:0.15em"><span></span></span></span></span></span></span></span></span></span>, <span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">t</mi><mi mathvariant="normal">d</mi><mi mathvariant="normal">I</mi><mi mathvariant="normal">n</mi><mi mathvariant="normal">s</mi></mrow><mo stretchy="false">(</mo><mn>3</mn><mo separator="true">,</mo><mn>5</mn><mo stretchy="false">)</mo><msub><mi>P</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PtdIns}(3,5)P_2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height:1em;vertical-align:-0.25em"></span><span class="mord"><span class="mord mathrm">PtdIns</span></span><span class="mopen">(</span><span class="mord">3</span><span class="mpunct">,</span><span class="mspace" style="margin-right:0.1667em"></span><span class="mord">5</span><span class="mclose">)</span><span class="mord"><span class="mord mathnormal" style="margin-right:0.13889em">P</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height:0.3011em"><span style="top:-2.55em;margin-left:-0.1389em;margin-right:0.05em"><span class="pstrut" style="height:2.7em"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">2</span></span></span></span><span class="vlist-s">â€‹</span></span><span class="vlist-r"><span class="vlist" style="height:0.15em"><span></span></span></span></span></span></span></span></span></span>, and <span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">t</mi><mi mathvariant="normal">d</mi><mi mathvariant="normal">I</mi><mi mathvariant="normal">n</mi><mi mathvariant="normal">s</mi></mrow><mo stretchy="false">(</mo><mn>3</mn><mo separator="true">,</mo><mn>4</mn><mo separator="true">,</mo><mn>5</mn><mo stretchy="false">)</mo><msub><mi>P</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PtdIns}(3,4,5)P_3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height:1em;vertical-align:-0.25em"></span><span class="mord"><span class="mord mathrm">PtdIns</span></span><span class="mopen">(</span><span class="mord">3</span><span class="mpunct">,</span><span class="mspace" style="margin-right:0.1667em"></span><span class="mord">4</span><span class="mpunct">,</span><span class="mspace" style="margin-right:0.1667em"></span><span class="mord">5</span><span class="mclose">)</span><span class="mord"><span class="mord mathnormal" style="margin-right:0.13889em">P</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height:0.3011em"><span style="top:-2.55em;margin-left:-0.1389em;margin-right:0.05em"><span class="pstrut" style="height:2.7em"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight">3</span></span></span></span><span class="vlist-s">â€‹</span></span><span class="vlist-r"><span class="vlist" style="height:0.15em"><span></span></span></span></span></span></span></span></span></span>) function in a mechanism by which an assorted group of signalling proteins, containing <span class="inline text-[1em] leading-7">PX domains</span>, <span class="inline text-[1em] leading-7">pleckstrin homology domains</span> (PH domains), <span class="inline text-[1em] leading-7">FYVE domains</span> or other phosphoinositide-binding domains, are recruited to various cellular membranes.</span>
<h1 id="phosphoinositide-3-kinases" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Phosphoinositide 3-kinases<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<h2 id="function" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Function<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">PI3Ks have been linked to an extraordinarily diverse group of cellular functions, including cell growth, proliferation, differentiation, motility, survival and intracellular trafficking. Many of these functions relate to the ability of class I PI3Ks to activate <span class="inline text-[1em] leading-7">protein kinase B</span> (PKB, aka Akt) as in the <span class="inline text-[1em] leading-7">PI3K/AKT/mTOR pathway</span>. The <span class="inline text-[1em] leading-7">p110Î´</span> and <span class="inline text-[1em] leading-7">p110Î³</span> isoforms regulate different aspects of immune responses. PI3Ks are also a key component of the <span class="inline text-[1em] leading-7">insulin signaling pathway</span>. Hence there is great interest in the role of PI3K signaling in <span class="inline text-[1em] leading-7">diabetes mellitus</span>. PI3K is also involved in interleukin-4 (IL-4) signaling in immune cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ebqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<h3 id="mechanism-1" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Mechanism<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The <span class="inline text-[1em] leading-7">pleckstrin homology domain</span> of <span class="inline text-[1em] leading-7">AKT</span> binds directly to <span class="inline text-[1em] leading-7">PtdIns(3,4,5)P3</span> and <span class="inline text-[1em] leading-7">PtdIns(3,4)P2</span>, which are produced by activated PI3Ks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_acqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup> Since PtdIns(3,4,5)P3 and PtdIns(3,4)P2 are restricted to the plasma membrane, this results in translocation of AKT to the plasma membrane. Likewise, the <span class="inline text-[1em] leading-7">phosphoinositide-dependent kinase-1</span> (PDK1 or, rarely referred to as PDPK1) also contains a pleckstrin homology domain that binds directly to PtdIns(3,4,5)P3 and PtdIns(3,4)P2, causing it to also translocate to the plasma membrane upon PI3K activation. The interaction of activated PDK1 and AKT allows AKT to become phosphorylated by PDK1 on threonine 308, leading to partial activation of AKT. Full activation of AKT occurs upon phosphorylation of serine 473 by the TORC2 complex of the <span class="inline text-[1em] leading-7">mTOR</span> protein kinase.</span>
<span class="mb-4 block break-words text-[1em] leading-7">The <span class="inline text-[1em] leading-7">PI3K/AKT pathway</span> has been shown to be required for an extremely diverse array of cellular activities - most notably cellular proliferation and survival. For example, it was shown to be involved in the protection of astrocytes from ceramide-induced apoptosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Many other proteins have been identified that are regulated by PtdIns(3,4,5)P3, including <span class="inline text-[1em] leading-7">Bruton&#x27;s tyrosine kinase</span> (BTK), General Receptor for Phosphoinositides-1 (GRP1), and the <span class="inline text-[1em] leading-7">O-linked N-acetylglucosamine (O-GlcNAc) transferase</span>.</span>
<span class="mb-4 block break-words text-[1em] leading-7">PtdIns(3,4,5)P3 also activates guanineâ€nucleotide exchange factors (GEFs) that activate the GTPase Rac1,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup> leading to <span class="inline text-[1em] leading-7">actin</span> polymerization and cytoskeletal rearrangement.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup></span>
<h3 id="cancers" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Cancers<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The class IA PI3K <span class="inline text-[1em] leading-7">p110Î±</span> is mutated in many cancers. Many of these mutations cause the kinase to be more active. It is the single most mutated kinase in <span class="inline text-[1em] leading-7">glioblastoma</span>, the most malignant primary brain tumor.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> The PtdIns(3,4,5)P_3 phosphatase <span class="inline text-[1em] leading-7">PTEN</span> that antagonises PI3K signaling is absent from many tumours. In addition, the epidermal growth factor receptor <span class="inline text-[1em] leading-7">EGFR</span> that functions upstream of PI3K is mutationally activated or overexpressed in cancer.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> Hence, PI3K activity contributes significantly to <span class="inline text-[1em] leading-7">cellular transformation</span> and the development of <span class="inline text-[1em] leading-7">cancer</span>. It has been shown that malignant B cells maintain a &quot;tonic&quot; activity of PI3K/Akt axis via upregulation of an adaptor protein GAB1, and this also allows B cells to survive targeted therapy with BCR inhibitors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_jfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup></span>
<h3 id="learning-and-memory" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Learning and memory<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">PI3Ks have also been implicated in <span class="inline text-[1em] leading-7">long-term potentiation</span> (LTP). Whether they are required for the expression or the induction of LTP is still debated. In mouse <span class="inline text-[1em] leading-7">hippocampal CA1</span> neurons, certain PI3Ks are complexed with <span class="inline text-[1em] leading-7">AMPA receptors</span> and compartmentalized at the <span class="inline text-[1em] leading-7">postsynaptic density</span> of <span class="inline text-[1em] leading-7">glutamatergic</span> synapses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> PI3K is activated downstream of NMDA receptor-dependent CaMKII activity,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_egabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> and it then facilitates the insertion of <span class="inline text-[1em] leading-7">AMPA-R</span> <span class="inline text-[1em] leading-7">GluR1</span> subunits into the plasma membrane. This suggests that PI3Ks are required for the expression of LTP. Furthermore, PI3K inhibitors abolished the expression of LTP in rat hippocampal CA1, but do not affect its induction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> Notably, the dependence of late-phase LTP expression on PI3Ks seems to decrease over time.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">However, another study found that PI3K inhibitors suppressed the induction, but not the expression, of LTP in mouse hippocampal CA1.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> The <span class="inline text-[1em] leading-7">PI3K pathway</span> also recruits many other proteins downstream, including <span class="inline text-[1em] leading-7">mTOR</span>,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup> <span class="inline text-[1em] leading-7">GSK3Î²</span>,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cgqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup> and <span class="inline text-[1em] leading-7">PSD-95</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ggqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup> The <span class="inline text-[1em] leading-7">PI3K-mTOR pathway</span> leads to the phosphorylation of <span class="inline text-[1em] leading-7">p70S6K</span>, a kinase that facilitates translational activity,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mgqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ngqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup> further suggesting that PI3Ks are required for the protein-synthesis phase of LTP induction instead.</span>
<h1 id="pi-3-kinases-as-protein-kinases" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">PI 3-kinases as protein kinases<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">Many PI3Ks, particularly class IA isoforms, exhibit serine/threonine protein kinase activity <em>in vitro</em> in addition to their primary lipid kinase function.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup> Historically, the physiological relevance of this activity <em>in vivo</em> was unclear; however, recent studies have demonstrated its role in specific contexts, such as PI3KÎ² promoting tumor progression through phosphorylation of O-GlcNAc transferase (OGT) and subsequent enhancement of protein O-GlcNAcylation and acetyl-CoA production.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup></span>
<h2 id="inhibition" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Inhibition<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">All PI3Ks are inhibited by the drugs wortmannin and LY294002, although certain members of the class II PI3K family show decreased sensitivity. Wortmannin shows better efficiency than LY294002 on the hotspot mutation positions (Glu542, Glu545, and His1047).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup></span>
<h3 id="pi3k-inhibitors-as-therapeutics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">PI3K inhibitors as therapeutics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">As wortmannin and LY294002 are broad-range inhibitors of PI3Ks and a number of unrelated proteins at higher concentrations, they are too toxic to be used as therapeutics. A number of pharmaceutical companies have thus developed PI3K isoform-specific inhibitors. As of October 2025, four PI3K inhibitors are approved by the FDA for routine clinical use in humans with cancers: the PI3KÎ´ inhibitor idelalisib (July 2014, NDA 206545, for relapsed chronic lymphocytic leukemia), the PI3KÎ± inhibitor alpelisib (May 2019, NDA 212526, for PIK3CA-mutated hormone receptor-positive, HER2-negative breast cancer), the dual PI3KÎ´/Î³ inhibitor duvelisib (September 2018, NDA 211155, for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma), and the PI3KÎ± inhibitor inavolisib (October 2024, NDA 219316, for endocrine-resistant PIK3CA-mutated hormone receptor-positive, HER2-negative breast cancer).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup> Co-targeted inhibition of the pathway with other pathways such as MAPK or PIM has been highlighted as a promising anti-cancer therapeutic strategy, which could offer benefit over the monotherapeutic approach by circumventing compensatory signalling, slowing the development of resistance and potentially allowing reduction of dosing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ajqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3414724/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3414724/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3414724/</a></span></div></li><li id="3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Giese N (2009). <a href="http://www.physorg.com/news156000728.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Cell pathway on overdrive prevents cancer response to dietary restriction&quot;</a>. PhysOrg.com. Retrieved 2009-04-22.</span></div></li><li id="4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kalaany NY, Sabatini DM (April 2009). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2692085" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Tumours with PI3K activation are resistant to dietary restriction&quot;</a>. <em>Nature</em>. <strong>458</strong> (7239): 725â€“31. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/2009Natur.458..725K" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2009Natur.458..725K</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2Fnature07782" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/nature07782</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2692085" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2692085</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/19279572" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">19279572</a>.</span></div></li><li id="5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Whitman M, Kaplan DR, Schaffhausen B, Cantley L, Roberts TM (1985). &quot;Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation&quot;. <em>Nature</em>. <strong>315</strong> (6016): 239â€“42. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/1985Natur.315..239W" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1985Natur.315..239W</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2F315239a0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/315239a0</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/2987699" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2987699</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:4337999" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4337999</a>.</span></div></li><li id="6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Whitman M, Downes CP, Keeler M, Keller T, Cantley L (April 1988). &quot;Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate&quot;. <em>Nature</em>. <strong>332</strong> (6165): 644â€“6. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/1988Natur.332..644W" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1988Natur.332..644W</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2F332644a0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/332644a0</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/2833705" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2833705</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:4326568" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4326568</a>.</span></div></li><li id="7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Auger KR, Serunian LA, Soltoff SP, Libby P, Cantley LC (April 1989). &quot;PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells&quot;. <em>Cell</em>. <strong>57</strong> (1): 167â€“75. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2F0092-8674%2889%2990182-7" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/0092-8674(89)90182-7</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/2467744" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2467744</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:22154860" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22154860</a>.</span></div></li><li id="8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Traynor-Kaplan AE, Harris AL, Thompson BL, Taylor P, Sklar LA (July 1988). &quot;An inositol tetrakisphosphate-containing phospholipid in activated neutrophils&quot;. <em>Nature</em>. <strong>334</strong> (6180): 353â€“6. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/1988Natur.334..353T" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1988Natur.334..353T</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2F334353a0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/334353a0</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/3393226" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3393226</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:4263472" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4263472</a>.</span></div></li><li id="9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Leevers SJ, Vanhaesebroeck B, Waterfield MD (April 1999). &quot;Signalling through phosphoinositide 3-kinases: the lipids take centre stage&quot;. <em>Current Opinion in Cell Biology</em>. <strong>11</strong> (2): 219â€“25. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2FS0955-0674%2899%2980029-5" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/S0955-0674(99)80029-5</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/10209156" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10209156</a>.</span></div></li><li id="10" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT (August 2017). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726441" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;The PI3K Pathway in Human Disease&quot;</a>. <em>Cell</em>. <strong>170</strong> (4): 605â€“635. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.cell.2017.07.029" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.cell.2017.07.029</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726441" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">5726441</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/28802037" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">28802037</a>.</span></div></li><li id="11" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Jean S, Kiger AA (March 2014). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937771" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Classes of phosphoinositide 3-kinases at a glance&quot;</a>. <em>Journal of Cell Science</em>. <strong>127</strong> (Pt 5): 923â€“8. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1242%2Fjcs.093773" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1242/jcs.093773</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937771" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3937771</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/24587488" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">24587488</a>.</span></div></li><li id="12" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Vanhaesebroeck B, Stephens L, Hawkins P (February 2012). &quot;PI3K signalling: the path to discovery and understanding&quot;. <em>Nature Reviews. Molecular Cell Biology</em>. <strong>13</strong> (3): 195â€“203. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2Fnrm3290" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/nrm3290</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22358332" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22358332</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:6999833" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6999833</a>.</span></div></li><li id="13" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Okkenhaug K (January 2013). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516760" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Signaling by the phosphoinositide 3-kinase family in immune cells&quot;</a>. <em>Annual Review of Immunology</em>. <strong>31</strong> (2): 675â€“704. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1146%2Fannurev-immunol-032712-095946" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1146/annurev-immunol-032712-095946</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516760" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4516760</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/23330955" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">23330955</a>.</span></div></li><li id="14" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Carpenter CL, Duckworth BC, Auger KR, Cohen B, Schaffhausen BS, Cantley LC (November 1990). <a href="https://doi.org/10.1016%2FS0021-9258%2817%2945429-9" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Purification and characterization of phosphoinositide 3-kinase from rat liver&quot;</a>. <em>The Journal of Biological Chemistry</em>. <strong>265</strong> (32): 19704â€“11. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2FS0021-9258%2817%2945429-9" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/S0021-9258(17)45429-9</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/2174051" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2174051</a>.</span></div></li><li id="15" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, et al. (March 1993). <a href="https://doi.org/10.1016%2F0092-8674%2893%2990404-E" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;SH2 domains recognize specific phosphopeptide sequences&quot;</a>. <em>Cell</em>. <strong>72</strong> (5): 767â€“78. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2F0092-8674%2893%2990404-E" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/0092-8674(93)90404-E</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/7680959" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7680959</a>.</span></div></li><li id="16" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Yoakim M, Hou W, Songyang Z, Liu Y, Cantley L, Schaffhausen B (September 1994). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC359119" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Genetic analysis of a phosphatidylinositol 3-kinase SH2 domain reveals determinants of specificity&quot;</a>. <em>Molecular and Cellular Biology</em>. <strong>14</strong> (9): 5929â€“38. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1128%2FMCB.14.9.5929" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1128/MCB.14.9.5929</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC359119" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">359119</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/8065326" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">8065326</a>.</span></div></li><li id="17" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Posor Y, Eichhorn-GrÃ¼nig M, Haucke V (June 2015). &quot;Phosphoinositides in endocytosis&quot;. <em>Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids</em>. <strong>1851</strong> (6): 794â€“804. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.bbalip.2014.09.014" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.bbalip.2014.09.014</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/25264171" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25264171</a>.</span></div></li><li id="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516760" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516760" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516760</a></span></div></li><li id="18" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Franke TF, Kaplan DR, Cantley LC, Toker A (January 1997). &quot;Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate&quot;. <em>Science</em>. <strong>275</strong> (5300): 665â€“8. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1126%2Fscience.275.5300.665" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1126/science.275.5300.665</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/9005852" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">9005852</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:31186873" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">31186873</a>.</span></div></li><li id="19" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">GÃ³mez Del Pulgar T, De Ceballos ML, GuzmÃ¡n M, Velasco G (September 2002). <a href="https://doi.org/10.1074%2Fjbc.M205797200" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway&quot;</a>. <em>The Journal of Biological Chemistry</em>. <strong>277</strong> (39): 36527â€“33. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1074%2Fjbc.M205797200" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1074/jbc.M205797200</a>. <span class="inline text-[1em] leading-7">hdl</span>:<a href="https://hdl.handle.net/10261%2F36487" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10261/36487</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/12133838" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">12133838</a>.</span></div></li><li id="20" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Welch HC, Coadwell WJ, Stephens LR, Hawkins PT (July 2003). <a href="https://doi.org/10.1016%2Fs0014-5793%2803%2900454-x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Phosphoinositide 3-kinase-dependent activation of Rac&quot;</a>. <em>FEBS Letters</em>. <strong>546</strong> (1): 93â€“7. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/2003FEBSL.546...93W" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2003FEBSL.546...93W</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fs0014-5793%2803%2900454-x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/s0014-5793(03)00454-x</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/12829242" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">12829242</a>.</span></div></li><li id="21" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Jaffe AB, Hall A (2005). &quot;Rho GTPases: biochemistry and biology&quot;. <em>Annual Review of Cell and Developmental Biology</em>. <strong>21</strong> : 247â€“69. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1146%2Fannurev.cellbio.21.020604.150721" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1146/annurev.cellbio.21.020604.150721</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/16212495" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">16212495</a>.</span></div></li><li id="22" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Bleeker FE, Lamba S, Zanon C, Molenaar RJ, Hulsebos TJ, Troost D, et al. (September 2014). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192443" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Mutational profiling of kinases in glioblastoma&quot;</a>. <em>BMC Cancer</em>. <strong>14</strong> 718. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1186%2F1471-2407-14-718" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1186/1471-2407-14-718</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192443" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4192443</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/25256166" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25256166</a>.</span></div></li><li id="23" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Bleeker FE, Molenaar RJ, Leenstra S (May 2012). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337398" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Recent advances in the molecular understanding of glioblastoma&quot;</a>. <em>Journal of Neuro-Oncology</em>. <strong>108</strong> (1): 11â€“27. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1007%2Fs11060-011-0793-0" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1007/s11060-011-0793-0</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337398" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3337398</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22270850" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22270850</a>.</span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8513669/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8513669/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8513669/</a></span></div></li><li id="24" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Man HY, Wang Q, Lu WY, Ju W, Ahmadian G, Liu L, et al. (May 2003). <a href="https://doi.org/10.1016%2FS0896-6273%2803%2900228-9" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Activation of PI3-kinase is required for AMPA receptor insertion during LTP of mEPSCs in cultured hippocampal neurons&quot;</a>. <em>Neuron</em>. <strong>38</strong> (4): 611â€“24. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2FS0896-6273%2803%2900228-9" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/S0896-6273(03)00228-9</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/12765612" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">12765612</a>.</span></div></li><li id="26" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Sanna PP, Cammalleri M, Berton F, Simpson C, Lutjens R, Bloom FE, Francesconi W (May 2002). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6758361" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Phosphatidylinositol 3-kinase is required for the expression but not for the induction or the maintenance of long-term potentiation in the hippocampal CA1 region&quot;</a>. <em>The Journal of Neuroscience</em>. <strong>22</strong> (9): 3359â€“65. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1523%2FJNEUROSCI.22-09-03359.2002" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1523/JNEUROSCI.22-09-03359.2002</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6758361" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6758361</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/11978812" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">11978812</a>.</span></div></li><li id="27" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Karpova A, Sanna PP, Behnisch T (February 2006). &quot;Involvement of multiple phosphatidylinositol 3-kinase-dependent pathways in the persistence of late-phase long term potentiation expression&quot;. <em>Neuroscience</em>. <strong>137</strong> (3): 833â€“41. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.neuroscience.2005.10.012" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.neuroscience.2005.10.012</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/16326012" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">16326012</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:38232127" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">38232127</a>.</span></div></li><li id="28" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Opazo P, Watabe AM, Grant SG, O&#x27;Dell TJ (May 2003). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742185" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Phosphatidylinositol 3-kinase regulates the induction of long-term potentiation through extracellular signal-related kinase-independent mechanisms&quot;</a>. <em>The Journal of Neuroscience</em>. <strong>23</strong> (9): 3679â€“88. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1523%2FJNEUROSCI.23-09-03679.2003" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1523/JNEUROSCI.23-09-03679.2003</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742185" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6742185</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/12736339" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">12736339</a>.</span></div></li><li id="32" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Cammalleri M, LÃ¼tjens R, Berton F, King AR, Simpson C, Francesconi W, Sanna PP (November 2003). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC283598" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Time-restricted role for dendritic activation of the mTOR-p70S6K pathway in the induction of late-phase long-term potentiation in the CA1&quot;</a>. <em>Proceedings of the National Academy of Sciences of the United States of America</em>. <strong>100</strong> (24): 14368â€“73. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/2003PNAS..10014368C" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2003PNAS..10014368C</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1073%2Fpnas.2336098100" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1073/pnas.2336098100</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC283598" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">283598</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/14623952" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">14623952</a>.</span></div></li><li id="30" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, et al. (March 2007). <a href="http://www.hal.inserm.fr/inserm-00776885" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;LTP inhibits LTD in the hippocampus via regulation of GSK3beta&quot;</a>. <em>Neuron</em>. <strong>53</strong> (5): 703â€“17. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.neuron.2007.01.029" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.neuron.2007.01.029</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/17329210" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">17329210</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:6903401" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6903401</a>.</span></div></li><li id="29" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Yang PC, Yang CH, Huang CC, Hsu KS (February 2008). <a href="https://doi.org/10.1074%2Fjbc.M706954200" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Phosphatidylinositol 3-kinase activation is required for stress protocol-induced modification of hippocampal synaptic plasticity&quot;</a>. <em>The Journal of Biological Chemistry</em>. <strong>283</strong> (5): 2631â€“43. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1074%2Fjbc.M706954200" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1074/jbc.M706954200</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/18057005" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">18057005</a>.</span></div></li><li id="31" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Toker A, Cantley LC (June 1997). <a href="https://doi.org/10.1038%2F42648" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Signalling through the lipid products of phosphoinositide-3-OH kinase&quot;</a>. <em>Nature</em>. <strong>387</strong> (6634): 673â€“6. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/1997Natur.387..673T" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1997Natur.387..673T</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2F42648" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/42648</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/9192891" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">9192891</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:4347728" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4347728</a>.</span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3601961/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3601961/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3601961/</a></span></div></li><li id="https://www.cell.com/molecular-cell/fulltext/S1097-2765(25)00186-8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cell.com/molecular-cell/fulltext/S1097-2765(25)00186-8" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cell.com/molecular-cell/fulltext/S1097-2765(25)00186-8</a></span></div></li><li id="33" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kumar DT, Doss CG (2016-01-01). <em>Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain: A Molecular Docking and Molecular Dynamics Approach</em>. Vol. 102. pp. 267â€“97. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fbs.apcsb.2015.09.008" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/bs.apcsb.2015.09.008</a>. <span class="inline text-[1em] leading-7">ISBN</span> 9780128047958. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/26827608" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">26827608</a>. <code class="text-fg-solar bg-fg-solar-opaque break-all rounded px-2 align-middle font-mono text-sm" node="[object Object]">{{cite book}}</code>: <code class="text-fg-solar bg-fg-solar-opaque break-all rounded px-2 align-middle font-mono text-sm" node="[object Object]">|journal=</code> ignored (help)</span></div></li><li id="34" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Sudhakar N, Priya Doss CG, Thirumal Kumar D, Chakraborty C, Anand K, Suresh M (2016-01-02). &quot;Deciphering the impact of somatic mutations in exon 20 and exon 9 of PIK3CA gene in breast tumors among Indian women through molecular dynamics approach&quot;. <em>Journal of Biomolecular Structure &amp; Dynamics</em>. <strong>34</strong> (1): 29â€“41. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1080%2F07391102.2015.1007483" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1080/07391102.2015.1007483</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/25679319" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25679319</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:205575161" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">205575161</a>.</span></div></li><li id="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=206545" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=206545" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=206545</a></span></div></li><li id="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alpelisib-metastatic-breast-cancer" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alpelisib-metastatic-breast-cancer" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alpelisib-metastatic-breast-cancer</a></span></div></li><li id="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=211155" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=211155" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=211155</a></span></div></li><li id="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive</a></span></div></li><li id="35" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Malone T, SchÃ¤fer L, Simon N, Heavey S, Cuffe S, Finn S, et al. (March 2020). <a href="https://discovery.ucl.ac.uk/id/eprint/10088376/1/1-s2.0-S0163725819302062-main.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer&quot;</a> (PDF). <em>Pharmacology &amp; Therapeutics</em>. <strong>207</strong> 107454. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.pharmthera.2019.107454" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.pharmthera.2019.107454</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/31836451" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">31836451</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:209357486" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">209357486</a>.</span></div></li><li id="36" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Luszczak S, Kumar C, Sathyadevan VK, Simpson BS, Gately KA, Whitaker HC, Heavey S (2020). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992635" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer&quot;</a>. <em>Signal Transduction and Targeted Therapy</em>. <strong>5</strong> 7. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2Fs41392-020-0109-y" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/s41392-020-0109-y</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992635" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6992635</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/32025342" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">32025342</a>.</span></div></li><li id="37" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Heavey S, Dowling P, Moore G, Barr MP, Kelly N, Maher SG, et al. (January 2018). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786033" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines&quot;</a>. <em>Scientific Reports</em>. <strong>8</strong> (1) 1652. <span class="inline text-[1em] leading-7">Bibcode</span>:<a href="https://ui.adsabs.harvard.edu/abs/2018NatSR...8.1652H" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2018NatSR...8.1652H</a>. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2Fs41598-018-19688-1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/s41598-018-19688-1</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786033" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">5786033</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/29374181" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">29374181</a>.</span></div></li><li id="38" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Heavey S, Godwin P, Baird AM, Barr MP, Umezawa K, Cuffe S, et al. (October 2014). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130730" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Strategic targeting of the PI3K-NFÎºB axis in cisplatin-resistant NSCLC&quot;</a>. <em>Cancer Biology &amp; Therapy</em>. <strong>15</strong> (10): 1367â€“77. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.4161%2Fcbt.29841" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.4161/cbt.29841</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130730" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4130730</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/25025901" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25025901</a>.</span></div></li><li id="39" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Heavey S, O&#x27;Byrne KJ, Gately K (April 2014). &quot;Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC&quot;. <em>Cancer Treatment Reviews</em>. <strong>40</strong> (3): 445â€“56. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.ctrv.2013.08.006" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.ctrv.2013.08.006</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/24055012" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">24055012</a>.</span></div></li></ol></div><div class="text-fg-secondary text-xs [&amp;_*]:mb-2"><hr class="border-border-l1 my-8 rounded-sm border-t"/>
<span class="mb-4 block break-words text-[1em] leading-7">The content is adapted from <a href="https://en.wikipedia.org/wiki/Phosphoinositide_3-kinase" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Wikipedia</a>, licensed under Creative Commons Attribution-ShareAlike 4.0 License.</span></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy" id="_R_" async=""></script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy\"}]\n"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Phosphoinositide_3-kinase\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Phosphoinositide_3-kinase\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Phosphoinositide_3-kinase\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T47e4,"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"# Phosphoinositide 3-kinase\n\n**Phosphoinositide 3-kinases** (**PI3Ks**), also called **phosphatidylinositol 3-kinases**, are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. \n\nPI3Ks are a family of related intracellular signal transducer enzymes capable of phosphorylating the 3 position hydroxyl group of the inositol ring of phosphatidylinositol (PtdIns).[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3414724/) The pathway, with oncogene PIK3CA and tumor suppressor gene PTEN, is implicated in the sensitivity of cancer tumors to insulin and IGF1, and in calorie restriction.[3][4]\n## Discovery\n\nThe discovery of PI3Ks by [Lewis Cantley](Lewis_C._Cantley \"Lewis C. Cantley\") and colleagues began with their identification of a previously unknown phosphoinositide kinase associated with the [polyoma](Polyoma \"Polyoma\") middle T protein.[5] They observed unique substrate specificity and chromatographic properties of the products of the lipid kinase, leading to the discovery that this phosphoinositide kinase had the unprecedented ability to phosphorylate phosphoinositides on the 3' position of the inositol ring.[6] Subsequently, Cantley and colleagues demonstrated that _in vivo_ the enzyme prefers PtdIns(4,5)P2 as a substrate, producing the novel phosphoinositide [PtdIns(3,4,5)P3](Phosphatidylinositol_\\(3%2C4%2C5\\)-trisphosphate \"Phosphatidylinositol \\(3,4,5\\)-trisphosphate\")[7] previously identified in neutrophils.[8]\n# Classes\n\nThe PI3K family is divided into four different classes: [Class I](Class_I_PI_3-kinases \"Class I PI 3-kinases\"), [Class II](Class_II_PI_3-kinases \"Class II PI 3-kinases\"), [Class III](Class_III_PI_3-kinase \"Class III PI 3-kinase\"), and Class IV. The classifications are based on primary structure, regulation, and _in vitro_ lipid substrate specificity.[9]\n\n### Class I\n\nClass I PI3Ks catalyze the conversion of [phosphatidylinositol (4,5)-bisphosphate](Phosphatidylinositol_\\(4%2C5\\)-bisphosphate \"Phosphatidylinositol \\(4,5\\)-bisphosphate\") (PI(4,5)P2) into [phosphatidylinositol (3,4,5)-trisphosphate](Phosphatidylinositol_\\(3%2C4%2C5\\)-trisphosphate \"Phosphatidylinositol \\(3,4,5\\)-trisphosphate\") (PI(3,4,5)P3) _in vivo_. While _in vitro_, they have also been shown to convert [phosphatidylinositol](Phosphatidylinositol \"Phosphatidylinositol\") (PI) into [phosphatidylinositol 3-phosphate](Phosphatidylinositol_3-phosphate \"Phosphatidylinositol 3-phosphate\") (PI3P) and [phosphatidylinositol 4-phosphate](Phosphatidylinositol_4-phosphate \"Phosphatidylinositol 4-phosphate\") (PI4P) into [phosphatidylinositol (3,4)-bisphosphate](Phosphatidylinositol_\\(3%2C4\\)-bisphosphate \"Phosphatidylinositol \\(3,4\\)-bisphosphate\") (PI(3,4)P2), these reactions are strongly disfavoured _in vivo_.[10][11][12][13] The PI3K is activated by [G protein-coupled receptors](G_protein-coupled_receptors \"G protein-coupled receptors\") and [tyrosine kinase receptors](Tyrosine_kinase_receptors \"Tyrosine kinase receptors\").[9]\n\nClass I PI3Ks are [heterodimeric](Heterodimeric \"Heterodimeric\") molecules composed of a regulatory and a catalytic [subunit](Protein_subunit \"Protein subunit\"); they are further divided between IA and IB subsets on sequence similarity. **Class IA PI3Ks** are composed of a heterodimer between a p110 catalytic subunit and a shorter regulatory subunit (often p85).[14] There are five variants of the regulatory subunit: the three [splice variants p85Î±, p55Î±, and p50Î±](PIK3R1 \"PIK3R1\"), [p85Î²](PIK3R2 \"PIK3R2\"), and [p55Î³](PIK3R3 \"PIK3R3\"). There are also three variants of the p110 catalytic subunit designated p110Î±, Î², or Î´ catalytic subunit. The first three regulatory subunits are all splice variants of the same gene (_Pik3r1_), the other two being expressed by other genes (Pik3r2 and Pik3r3, p85Î², and p55Î³, respectively). The most highly expressed regulatory subunit is p85Î±; all three catalytic subunits are expressed by separate genes (_Pik3ca_ , _Pik3cb_ , and _Pik3cd_ for [p110Î±](P110%CE%B1 \"P110Î±\"), [p110Î²](P110%CE%B2 \"P110Î²\"), and [p110Î´](P110%CE%B4 \"P110Î´\"), respectively). The first two p110 isoforms (Î± and Î²) are expressed in all cells, but p110Î´ is expressed primarily in [leukocytes](Leukocytes \"Leukocytes\"), and it has been suggested that it evolved in parallel with the adaptive immune system. The regulatory p101 and catalytic [p110Î³](P110%CE%B3 \"P110Î³\") subunits comprise the **class IB PI3Ks** and are encoded by a single gene each (_Pik3cg_ for [p110Î³](P110%CE%B3 \"P110Î³\") and _Pik3r5_ for p101). \n\nThe p85 subunits contain [SH2](SH2_domain \"SH2 domain\") and [SH3](SH3_domain \"SH3 domain\") domains ([Online Mendelian Inheritance in Man](Online_Mendelian_Inheritance_in_Man \"Online Mendelian Inheritance in Man\") (OMIM): [171833](https://omim.org/entry/171833)). The SH2 domains bind preferentially to phosphorylated tyrosine residues in the amino acid sequence context Y-X-X-M.[15][16]\n\n### Classes II and III\n\n[Class II](Class_II_PI_3-kinases \"Class II PI 3-kinases\") and [III](Class_III_PI_3-kinase \"Class III PI 3-kinase\") PI3Ks are differentiated from the Class I by their structure and function. The distinct feature of Class II PI3Ks is the C-terminal C2 domain. This domain lacks critical [Asp](Aspartic_acid \"Aspartic acid\") residues to coordinate binding of Ca2+, which suggests class II PI3Ks bind lipids in a Ca2+-independent manner. \n\nClass II comprises three catalytic isoforms (C2Î±, C2Î², and C2Î³), but, unlike Classes I and III, no regulatory proteins. Class II catalyse the production of PI(3)P from PI and PI(3,4)P2 from PI(4)P; however, little is known about their role in immune cells. PI(3,4)P2 has, however, been shown to play a role in the invagination phase of clathrin-mediated endocytosis.[17] C2Î± and C2Î² are expressed through the body, but expression of C2Î³ is limited to [hepatocytes](Hepatocytes \"Hepatocytes\"). \n\nClass III PI3Ks produce only PI(3)P from PI [9] but are more similar to Class I in structure, as they exist as heterodimers of a catalytic ([Vps34](Vps34 \"Vps34\")) and a regulatory (Vps15/p150) subunits. Class III seems to be primarily involved in the trafficking of proteins and vesicles. There is, however, evidence to show that they are able to contribute to the effectiveness of several process important to immune cells, not least [phagocytosis](Phagocytosis \"Phagocytosis\"). \n\n### Class IV\n\nA group of more distantly related enzymes is sometimes referred to as class IV PI3Ks. It is composed of [ataxia telangiectasia mutated](Ataxia_telangiectasia_mutated \"Ataxia telangiectasia mutated\") (ATM), [ataxia telangiectasia and Rad3 related](Ataxia_telangiectasia_and_Rad3_related \"Ataxia telangiectasia and Rad3 related\") (ATR), DNA-dependent protein kinase (DNA-PK) and [mammalian target of rapamycin](Mammalian_target_of_rapamycin \"Mammalian target of rapamycin\") (mTOR). They are protein serine/threonine kinases.\n# Human genes\n\n| group              | gene      | protein                                      | aliases                          | EC number                  |\n|--------------------|-----------|----------------------------------------------|----------------------------------|----------------------------|\n| class 1 catalytic  | [PIK3CA] | PI3K, catalytic, alpha polypeptide           | p110-Î±                           | [2.7.1.153]                |\n|                    | [PIK3CB] | PI3K, catalytic, beta polypeptide            | p110-Î²                           | [2.7.1.153]                |\n|                    | [PIK3CG] | PI3K, catalytic, gamma polypeptide           | p110-Î³                           | [2.7.1.153]                |\n|                    | [PIK3CD] | PI3K, catalytic, delta polypeptide           | p110-Î´                           | [2.7.1.153]                |\n| class 1 regulatory | [PIK3R1] | PI3K, regulatory subunit 1 (alpha)           | p85-Î±, p55-Î±, p50-Î± (splice variants) | N/A                        |\n|                    | [PIK3R2] | PI3K, regulatory subunit 2 (beta)            | p85-Î²                            | N/A                        |\n|                    | [PIK3R3] | PI3K, regulatory subunit 3 (gamma)           | p55-Î³                            | N/A                        |\n|                    | [PIK3R4] | PI3K, regulatory subunit 4                  | p150                             | N/A                        |\n|                    | [PIK3R5] | PI3K, regulatory subunit 5                  | p101                             | N/A                        |\n|                    | PIK3R6   | PI3K, regulatory subunit 6                  | p87                              | N/A                        |\n| class 2            | [PIK3C2A]| PI3K, class 2, alpha polypeptide             | PI3K-C2Î±                         | [2.7.1.154]                |\n|                    | [PIK3C2B]| PI3K, class 2, beta polypeptide              | PI3K-C2Î²                         | [2.7.1.154]                |\n|                    | [PIK3C2G]| PI3K, class 2, gamma polypeptide             | PI3K-C2Î³                         | [2.7.1.154]                |\n| class 3            | [PIK3C3] | PI3K, class 3                               | Vps34                            | [2.7.1.137]                |\n## Mechanism\n\nThe various 3-phosphorylated [phosphoinositides](Phosphoinositides \"Phosphoinositides\") that are produced by PI3Ks (\\( \\mathrm{PtdIns3P} \\), \\( \\mathrm{PtdIns}(3,4)P_2 \\), \\( \\mathrm{PtdIns}(3,5)P_2 \\), and \\( \\mathrm{PtdIns}(3,4,5)P_3 \\)) function in a mechanism by which an assorted group of signalling proteins, containing [PX domains](PX_domain \"PX domain\"), [pleckstrin homology domains](Pleckstrin_homology_domain \"Pleckstrin homology domain\") (PH domains), [FYVE domains](FYVE_domains \"FYVE domains\") or other phosphoinositide-binding domains, are recruited to various cellular membranes.\n# Phosphoinositide 3-kinases\n\n## Function\n\nPI3Ks have been linked to an extraordinarily diverse group of cellular functions, including cell growth, proliferation, differentiation, motility, survival and intracellular trafficking. Many of these functions relate to the ability of class I PI3Ks to activate [protein kinase B](Protein_kinase_B \"Protein kinase B\") (PKB, aka Akt) as in the [PI3K/AKT/mTOR pathway](PI3K/AKT/mTOR_pathway \"PI3K/AKT/mTOR pathway\"). The [p110Î´](P110%CE%B4 \"P110Î´\") and [p110Î³](P110%CE%B3 \"P110Î³\") isoforms regulate different aspects of immune responses. PI3Ks are also a key component of the [insulin signaling pathway](Insulin_signal_transduction_pathway_and_regulation_of_blood_glucose \"Insulin signal transduction pathway and regulation of blood glucose\"). Hence there is great interest in the role of PI3K signaling in [diabetes mellitus](Diabetes_mellitus \"Diabetes mellitus\"). PI3K is also involved in interleukin-4 (IL-4) signaling in immune cells.[](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516760)\n\n### Mechanism\n\nThe [pleckstrin homology domain](Pleckstrin_homology_domain \"Pleckstrin homology domain\") of [AKT](AKT \"AKT\") binds directly to [PtdIns(3,4,5)P3](Phosphatidylinositol_\\(3%2C4%2C5\\)-trisphosphate \"Phosphatidylinositol \\(3,4,5\\)-trisphosphate\") and [PtdIns(3,4)P2](PtdIns\\(3%2C4\\)P2 \"PtdIns\\(3,4\\)P2\"), which are produced by activated PI3Ks.[18] Since PtdIns(3,4,5)P3 and PtdIns(3,4)P2 are restricted to the plasma membrane, this results in translocation of AKT to the plasma membrane. Likewise, the [phosphoinositide-dependent kinase-1](Phosphoinositide-dependent_kinase-1 \"Phosphoinositide-dependent kinase-1\") (PDK1 or, rarely referred to as PDPK1) also contains a pleckstrin homology domain that binds directly to PtdIns(3,4,5)P3 and PtdIns(3,4)P2, causing it to also translocate to the plasma membrane upon PI3K activation. The interaction of activated PDK1 and AKT allows AKT to become phosphorylated by PDK1 on threonine 308, leading to partial activation of AKT. Full activation of AKT occurs upon phosphorylation of serine 473 by the TORC2 complex of the [mTOR](MTOR \"MTOR\") protein kinase. \n\nThe [PI3K/AKT pathway](PI3K/AKT_pathway \"PI3K/AKT pathway\") has been shown to be required for an extremely diverse array of cellular activities - most notably cellular proliferation and survival. For example, it was shown to be involved in the protection of astrocytes from ceramide-induced apoptosis.[19]\n\nMany other proteins have been identified that are regulated by PtdIns(3,4,5)P3, including [Bruton's tyrosine kinase](Bruton's_tyrosine_kinase \"Bruton's tyrosine kinase\") (BTK), General Receptor for Phosphoinositides-1 (GRP1), and the [O-linked N-acetylglucosamine (O-GlcNAc) transferase](OGT_\\(gene\\) \"OGT \\(gene\\)\"). \n\nPtdIns(3,4,5)P3 also activates guanineâ€nucleotide exchange factors (GEFs) that activate the GTPase Rac1,[20] leading to [actin](Actin \"Actin\") polymerization and cytoskeletal rearrangement.[21]\n\n### Cancers\n\nThe class IA PI3K [p110Î±](P110%CE%B1 \"P110Î±\") is mutated in many cancers. Many of these mutations cause the kinase to be more active. It is the single most mutated kinase in [glioblastoma](Glioblastoma \"Glioblastoma\"), the most malignant primary brain tumor.[22] The PtdIns(3,4,5)P_3 phosphatase [PTEN](PTEN_\\(gene\\) \"PTEN \\(gene\\)\") that antagonises PI3K signaling is absent from many tumours. In addition, the epidermal growth factor receptor [EGFR](Epidermal_growth_factor_receptor \"Epidermal growth factor receptor\") that functions upstream of PI3K is mutationally activated or overexpressed in cancer.[22][23] Hence, PI3K activity contributes significantly to [cellular transformation](Cellular_transformation \"Cellular transformation\") and the development of [cancer](Cancer \"Cancer\"). It has been shown that malignant B cells maintain a \"tonic\" activity of PI3K/Akt axis via upregulation of an adaptor protein GAB1, and this also allows B cells to survive targeted therapy with BCR inhibitors.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8513669/)\n\n### Learning and memory\n\nPI3Ks have also been implicated in [long-term potentiation](Long-term_potentiation \"Long-term potentiation\") (LTP). Whether they are required for the expression or the induction of LTP is still debated. In mouse [hippocampal CA1](Hippocampal_ca1_region \"Hippocampal ca1 region\") neurons, certain PI3Ks are complexed with [AMPA receptors](AMPA_receptor \"AMPA receptor\") and compartmentalized at the [postsynaptic density](Postsynaptic_density \"Postsynaptic density\") of [glutamatergic](Glutamatergic \"Glutamatergic\") synapses.[24] PI3K is activated downstream of NMDA receptor-dependent CaMKII activity,[24] and it then facilitates the insertion of [AMPA-R](AMPA-R \"AMPA-R\") [GluR1](GluR1 \"GluR1\") subunits into the plasma membrane. This suggests that PI3Ks are required for the expression of LTP. Furthermore, PI3K inhibitors abolished the expression of LTP in rat hippocampal CA1, but do not affect its induction.[26] Notably, the dependence of late-phase LTP expression on PI3Ks seems to decrease over time.[27]\n\nHowever, another study found that PI3K inhibitors suppressed the induction, but not the expression, of LTP in mouse hippocampal CA1.[28] The [PI3K pathway](PI3K/AKT/mTOR_pathway \"PI3K/AKT/mTOR pathway\") also recruits many other proteins downstream, including [mTOR](MTOR \"MTOR\"),[32] [GSK3Î²](GSK3%CE%B2 \"GSK3Î²\"),[30] and [PSD-95](PSD-95 \"PSD-95\").[29] The [PI3K-mTOR pathway](PI3K/AKT/mTOR_pathway \"PI3K/AKT/mTOR pathway\") leads to the phosphorylation of [p70S6K](P70S6K \"P70S6K\"), a kinase that facilitates translational activity,[31][32] further suggesting that PI3Ks are required for the protein-synthesis phase of LTP induction instead.\n# PI 3-kinases as protein kinases\n\nMany PI3Ks, particularly class IA isoforms, exhibit serine/threonine protein kinase activity _in vitro_ in addition to their primary lipid kinase function.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3601961/) Historically, the physiological relevance of this activity _in vivo_ was unclear; however, recent studies have demonstrated its role in specific contexts, such as PI3KÎ² promoting tumor progression through phosphorylation of O-GlcNAc transferase (OGT) and subsequent enhancement of protein O-GlcNAcylation and acetyl-CoA production.[](https://www.cell.com/molecular-cell/fulltext/S1097-2765(25)00186-8)\n## Inhibition\n\nAll PI3Ks are inhibited by the drugs wortmannin and LY294002, although certain members of the class II PI3K family show decreased sensitivity. Wortmannin shows better efficiency than LY294002 on the hotspot mutation positions (Glu542, Glu545, and His1047).[33][34]\n\n### PI3K inhibitors as therapeutics\n\nAs wortmannin and LY294002 are broad-range inhibitors of PI3Ks and a number of unrelated proteins at higher concentrations, they are too toxic to be used as therapeutics. A number of pharmaceutical companies have thus developed PI3K isoform-specific inhibitors. As of October 2025, four PI3K inhibitors are approved by the FDA for routine clinical use in humans with cancers: the PI3KÎ´ inhibitor idelalisib (July 2014, NDA 206545, for relapsed chronic lymphocytic leukemia), the PI3KÎ± inhibitor alpelisib (May 2019, NDA 212526, for PIK3CA-mutated hormone receptor-positive, HER2-negative breast cancer), the dual PI3KÎ´/Î³ inhibitor duvelisib (September 2018, NDA 211155, for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma), and the PI3KÎ± inhibitor inavolisib (October 2024, NDA 219316, for endocrine-resistant PIK3CA-mutated hormone receptor-positive, HER2-negative breast cancer).[](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process\u0026ApplNo=206545)[](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alpelisib-metastatic-breast-cancer)[](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process\u0026ApplNo=211155)[](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive) Co-targeted inhibition of the pathway with other pathways such as MAPK or PIM has been highlighted as a promising anti-cancer therapeutic strategy, which could offer benefit over the monotherapeutic approach by circumventing compensatory signalling, slowing the development of resistance and potentially allowing reduction of dosing.[35][36][37][38][39]"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761885809426,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"** [PDB](Protein_Data_Bank \\\"Protein Data Bank\\\"): [2chz](https://www.rcsb.org/structure/2chz)â€‹; Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, et al. (May 2006). [\\\"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2946820). _Cell_. **125** (4): 733â€“47\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.cell.2006.03.035](https://doi.org/10.1016%2Fj.cell.2006.03.035). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2946820](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2946820). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16647110](https://pubmed.ncbi.nlm.nih.gov/16647110).\",\"description\":\"1. **^** [PDB](Protein_Data_Bank \\\"Protein Data Bank\\\"): [2chz](https://www.rcsb.org/structure/2chz)â€‹; Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, et al. (May 2006). [\\\"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2946820). _Cell_. **125** (4): 733â€“47\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.cell.2006.03.035](https://doi.org/10.1016%2Fj.cell.2006.03.035). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2946820](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2946820). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16647110](https://pubmed.ncbi.nlm.nih.gov/16647110).\",\"url\":\"Protein_Data_Bank \\\"Protein Data Bank\\\"\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"** [\\\"myo-inositol\\\"](https://web.archive.org/web/20110806104525/http://www.chem.qmul.ac.uk/iupac/cyclitol/myo.html). Archived from [the original](http://www.chem.qmul.ac.uk/iupac/cyclitol/myo.html) on 2011-08-06. Retrieved 2006-01-28.\",\"description\":\"2. **^** [\\\"myo-inositol\\\"](https://web.archive.org/web/20110806104525/http://www.chem.qmul.ac.uk/iupac/cyclitol/myo.html). Archived from [the original](http://www.chem.qmul.ac.uk/iupac/cyclitol/myo.html) on 2011-08-06. Retrieved 2006-01-28.\",\"url\":\"https://web.archive.org/web/20110806104525/http://www.chem.qmul.ac.uk/iupac/cyclitol/myo.html\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"** Giese N (2009). [\\\"Cell pathway on overdrive prevents cancer response to dietary restriction\\\"](http://www.physorg.com/news156000728.html). PhysOrg.com. Retrieved 2009-04-22.\",\"description\":\"3. **^** Giese N (2009). [\\\"Cell pathway on overdrive prevents cancer response to dietary restriction\\\"](http://www.physorg.com/news156000728.html). PhysOrg.com. Retrieved 2009-04-22.\",\"url\":\"http://www.physorg.com/news156000728.html\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"** Kalaany NY, Sabatini DM (April 2009). [\\\"Tumours with PI3K activation are resistant to dietary restriction\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2692085). _Nature_. **458** (7239): 725â€“31\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2009Natur.458..725K](https://ui.adsabs.harvard.edu/abs/2009Natur.458..725K). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/nature07782](https://doi.org/10.1038%2Fnature07782). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2692085](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2692085). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19279572](https://pubmed.ncbi.nlm.nih.gov/19279572).\",\"description\":\"4. **^** Kalaany NY, Sabatini DM (April 2009). [\\\"Tumours with PI3K activation are resistant to dietary restriction\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2692085). _Nature_. **458** (7239): 725â€“31\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2009Natur.458..725K](https://ui.adsabs.harvard.edu/abs/2009Natur.458..725K). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/nature07782](https://doi.org/10.1038%2Fnature07782). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2692085](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2692085). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19279572](https://pubmed.ncbi.nlm.nih.gov/19279572).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2692085\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"** Whitman M, Kaplan DR, Schaffhausen B, Cantley L, Roberts TM (1985). \\\"Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation\\\". _Nature_. **315** (6016): 239â€“42\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[1985Natur.315..239W](https://ui.adsabs.harvard.edu/abs/1985Natur.315..239W). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/315239a0](https://doi.org/10.1038%2F315239a0). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [2987699](https://pubmed.ncbi.nlm.nih.gov/2987699). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [4337999](https://api.semanticscholar.org/CorpusID:4337999).\",\"description\":\"5. **^** Whitman M, Kaplan DR, Schaffhausen B, Cantley L, Roberts TM (1985). \\\"Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation\\\". _Nature_. **315** (6016): 239â€“42\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[1985Natur.315..239W](https://ui.adsabs.harvard.edu/abs/1985Natur.315..239W). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/315239a0](https://doi.org/10.1038%2F315239a0). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [2987699](https://pubmed.ncbi.nlm.nih.gov/2987699). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [4337999](https://api.semanticscholar.org/CorpusID:4337999).\",\"url\":\"Bibcode_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"** Whitman M, Downes CP, Keeler M, Keller T, Cantley L (April 1988). \\\"Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate\\\". _Nature_. **332** (6165): 644â€“6\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[1988Natur.332..644W](https://ui.adsabs.harvard.edu/abs/1988Natur.332..644W). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/332644a0](https://doi.org/10.1038%2F332644a0). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [2833705](https://pubmed.ncbi.nlm.nih.gov/2833705). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [4326568](https://api.semanticscholar.org/CorpusID:4326568).\",\"description\":\"6. **^** Whitman M, Downes CP, Keeler M, Keller T, Cantley L (April 1988). \\\"Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate\\\". _Nature_. **332** (6165): 644â€“6\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[1988Natur.332..644W](https://ui.adsabs.harvard.edu/abs/1988Natur.332..644W). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/332644a0](https://doi.org/10.1038%2F332644a0). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [2833705](https://pubmed.ncbi.nlm.nih.gov/2833705). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [4326568](https://api.semanticscholar.org/CorpusID:4326568).\",\"url\":\"Bibcode_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"** Auger KR, Serunian LA, Soltoff SP, Libby P, Cantley LC (April 1989). \\\"PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells\\\". _Cell_. **57** (1): 167â€“75\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/0092-8674(89)90182-7](https://doi.org/10.1016%2F0092-8674%2889%2990182-7). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [2467744](https://pubmed.ncbi.nlm.nih.gov/2467744). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [22154860](https://api.semanticscholar.org/CorpusID:22154860).\",\"description\":\"7. **^** Auger KR, Serunian LA, Soltoff SP, Libby P, Cantley LC (April 1989). \\\"PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells\\\". _Cell_. **57** (1): 167â€“75\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/0092-8674(89)90182-7](https://doi.org/10.1016%2F0092-8674%2889%2990182-7). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [2467744](https://pubmed.ncbi.nlm.nih.gov/2467744). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [22154860](https://api.semanticscholar.org/CorpusID:22154860).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"** Traynor-Kaplan AE, Harris AL, Thompson BL, Taylor P, Sklar LA (July 1988). \\\"An inositol tetrakisphosphate-containing phospholipid in activated neutrophils\\\". _Nature_. **334** (6180): 353â€“6\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[1988Natur.334..353T](https://ui.adsabs.harvard.edu/abs/1988Natur.334..353T). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/334353a0](https://doi.org/10.1038%2F334353a0). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [3393226](https://pubmed.ncbi.nlm.nih.gov/3393226). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [4263472](https://api.semanticscholar.org/CorpusID:4263472).\",\"description\":\"8. **^** Traynor-Kaplan AE, Harris AL, Thompson BL, Taylor P, Sklar LA (July 1988). \\\"An inositol tetrakisphosphate-containing phospholipid in activated neutrophils\\\". _Nature_. **334** (6180): 353â€“6\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[1988Natur.334..353T](https://ui.adsabs.harvard.edu/abs/1988Natur.334..353T). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/334353a0](https://doi.org/10.1038%2F334353a0). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [3393226](https://pubmed.ncbi.nlm.nih.gov/3393226). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [4263472](https://api.semanticscholar.org/CorpusID:4263472).\",\"url\":\"Bibcode_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"_**a**_ _**b**_ _**c**_ Leevers SJ, Vanhaesebroeck B, Waterfield MD (April 1999). \\\"Signalling through phosphoinositide 3-kinases: the lipids take centre stage\\\". _Current Opinion in Cell Biology_. **11** (2): 219â€“25\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/S0955-0674(99)80029-5](https://doi.org/10.1016%2FS0955-0674%2899%2980029-5). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [10209156](https://pubmed.ncbi.nlm.nih.gov/10209156).\",\"description\":\"9. ^ _**a**_ _**b**_ _**c**_ Leevers SJ, Vanhaesebroeck B, Waterfield MD (April 1999). \\\"Signalling through phosphoinositide 3-kinases: the lipids take centre stage\\\". _Current Opinion in Cell Biology_. **11** (2): 219â€“25\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/S0955-0674(99)80029-5](https://doi.org/10.1016%2FS0955-0674%2899%2980029-5). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [10209156](https://pubmed.ncbi.nlm.nih.gov/10209156).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"** Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT (August 2017). [\\\"The PI3K Pathway in Human Disease\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726441). _Cell_. **170** (4): 605â€“635\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.cell.2017.07.029](https://doi.org/10.1016%2Fj.cell.2017.07.029). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5726441](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726441). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28802037](https://pubmed.ncbi.nlm.nih.gov/28802037).\",\"description\":\"10. **^** Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT (August 2017). [\\\"The PI3K Pathway in Human Disease\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726441). _Cell_. **170** (4): 605â€“635\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.cell.2017.07.029](https://doi.org/10.1016%2Fj.cell.2017.07.029). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5726441](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726441). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28802037](https://pubmed.ncbi.nlm.nih.gov/28802037).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726441\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"** Jean S, Kiger AA (March 2014). [\\\"Classes of phosphoinositide 3-kinases at a glance\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937771). _Journal of Cell Science_. **127** (Pt 5): 923â€“8\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1242/jcs.093773](https://doi.org/10.1242%2Fjcs.093773). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3937771](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937771). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24587488](https://pubmed.ncbi.nlm.nih.gov/24587488).\",\"description\":\"11. **^** Jean S, Kiger AA (March 2014). [\\\"Classes of phosphoinositide 3-kinases at a glance\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937771). _Journal of Cell Science_. **127** (Pt 5): 923â€“8\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1242/jcs.093773](https://doi.org/10.1242%2Fjcs.093773). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3937771](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937771). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24587488](https://pubmed.ncbi.nlm.nih.gov/24587488).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937771\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"** Vanhaesebroeck B, Stephens L, Hawkins P (February 2012). \\\"PI3K signalling: the path to discovery and understanding\\\". _Nature Reviews. Molecular Cell Biology_. **13** (3): 195â€“203\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/nrm3290](https://doi.org/10.1038%2Fnrm3290). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22358332](https://pubmed.ncbi.nlm.nih.gov/22358332). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [6999833](https://api.semanticscholar.org/CorpusID:6999833).\",\"description\":\"12. **^** Vanhaesebroeck B, Stephens L, Hawkins P (February 2012). \\\"PI3K signalling: the path to discovery and understanding\\\". _Nature Reviews. Molecular Cell Biology_. **13** (3): 195â€“203\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/nrm3290](https://doi.org/10.1038%2Fnrm3290). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22358332](https://pubmed.ncbi.nlm.nih.gov/22358332). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [6999833](https://api.semanticscholar.org/CorpusID:6999833).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"** Okkenhaug K (January 2013). [\\\"Signaling by the phosphoinositide 3-kinase family in immune cells\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516760). _Annual Review of Immunology_. **31** (2): 675â€“704\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1146/annurev-immunol-032712-095946](https://doi.org/10.1146%2Fannurev-immunol-032712-095946). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4516760](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516760). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23330955](https://pubmed.ncbi.nlm.nih.gov/23330955).\",\"description\":\"13. **^** Okkenhaug K (January 2013). [\\\"Signaling by the phosphoinositide 3-kinase family in immune cells\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516760). _Annual Review of Immunology_. **31** (2): 675â€“704\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1146/annurev-immunol-032712-095946](https://doi.org/10.1146%2Fannurev-immunol-032712-095946). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4516760](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516760). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [23330955](https://pubmed.ncbi.nlm.nih.gov/23330955).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516760\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"** Carpenter CL, Duckworth BC, Auger KR, Cohen B, Schaffhausen BS, Cantley LC (November 1990). [\\\"Purification and characterization of phosphoinositide 3-kinase from rat liver\\\"](https://doi.org/10.1016%2FS0021-9258%2817%2945429-9). _The Journal of Biological Chemistry_. **265** (32): 19704â€“11\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/S0021-9258(17)45429-9](https://doi.org/10.1016%2FS0021-9258%2817%2945429-9). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [2174051](https://pubmed.ncbi.nlm.nih.gov/2174051).\",\"description\":\"14. **^** Carpenter CL, Duckworth BC, Auger KR, Cohen B, Schaffhausen BS, Cantley LC (November 1990). [\\\"Purification and characterization of phosphoinositide 3-kinase from rat liver\\\"](https://doi.org/10.1016%2FS0021-9258%2817%2945429-9). _The Journal of Biological Chemistry_. **265** (32): 19704â€“11\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/S0021-9258(17)45429-9](https://doi.org/10.1016%2FS0021-9258%2817%2945429-9). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [2174051](https://pubmed.ncbi.nlm.nih.gov/2174051).\",\"url\":\"https://doi.org/10.1016%2FS0021-9258%2817%2945429-9\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"** Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, et al. (March 1993). [\\\"SH2 domains recognize specific phosphopeptide sequences\\\"](https://doi.org/10.1016%2F0092-8674%2893%2990404-E). _Cell_. **72** (5): 767â€“78\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/0092-8674(93)90404-E](https://doi.org/10.1016%2F0092-8674%2893%2990404-E). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7680959](https://pubmed.ncbi.nlm.nih.gov/7680959).\",\"description\":\"15. **^** Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, et al. (March 1993). [\\\"SH2 domains recognize specific phosphopeptide sequences\\\"](https://doi.org/10.1016%2F0092-8674%2893%2990404-E). _Cell_. **72** (5): 767â€“78\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/0092-8674(93)90404-E](https://doi.org/10.1016%2F0092-8674%2893%2990404-E). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7680959](https://pubmed.ncbi.nlm.nih.gov/7680959).\",\"url\":\"https://doi.org/10.1016%2F0092-8674%2893%2990404-E\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"** Yoakim M, Hou W, Songyang Z, Liu Y, Cantley L, Schaffhausen B (September 1994). [\\\"Genetic analysis of a phosphatidylinositol 3-kinase SH2 domain reveals determinants of specificity\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC359119). _Molecular and Cellular Biology_. **14** (9): 5929â€“38\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/MCB.14.9.5929](https://doi.org/10.1128%2FMCB.14.9.5929). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [359119](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC359119). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [8065326](https://pubmed.ncbi.nlm.nih.gov/8065326).\",\"description\":\"16. **^** Yoakim M, Hou W, Songyang Z, Liu Y, Cantley L, Schaffhausen B (September 1994). [\\\"Genetic analysis of a phosphatidylinositol 3-kinase SH2 domain reveals determinants of specificity\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC359119). _Molecular and Cellular Biology_. **14** (9): 5929â€“38\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1128/MCB.14.9.5929](https://doi.org/10.1128%2FMCB.14.9.5929). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [359119](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC359119). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [8065326](https://pubmed.ncbi.nlm.nih.gov/8065326).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC359119\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"** Posor Y, Eichhorn-GrÃ¼nig M, Haucke V (June 2015). \\\"Phosphoinositides in endocytosis\\\". _Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids_. **1851** (6): 794â€“804\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.bbalip.2014.09.014](https://doi.org/10.1016%2Fj.bbalip.2014.09.014). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25264171](https://pubmed.ncbi.nlm.nih.gov/25264171).\",\"description\":\"17. **^** Posor Y, Eichhorn-GrÃ¼nig M, Haucke V (June 2015). \\\"Phosphoinositides in endocytosis\\\". _Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids_. **1851** (6): 794â€“804\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.bbalip.2014.09.014](https://doi.org/10.1016%2Fj.bbalip.2014.09.014). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25264171](https://pubmed.ncbi.nlm.nih.gov/25264171).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"** Franke TF, Kaplan DR, Cantley LC, Toker A (January 1997). \\\"Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate\\\". _Science_. **275** (5300): 665â€“8\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/science.275.5300.665](https://doi.org/10.1126%2Fscience.275.5300.665). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [9005852](https://pubmed.ncbi.nlm.nih.gov/9005852). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [31186873](https://api.semanticscholar.org/CorpusID:31186873).\",\"description\":\"18. **^** Franke TF, Kaplan DR, Cantley LC, Toker A (January 1997). \\\"Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate\\\". _Science_. **275** (5300): 665â€“8\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1126/science.275.5300.665](https://doi.org/10.1126%2Fscience.275.5300.665). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [9005852](https://pubmed.ncbi.nlm.nih.gov/9005852). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [31186873](https://api.semanticscholar.org/CorpusID:31186873).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"** GÃ³mez Del Pulgar T, De Ceballos ML, GuzmÃ¡n M, Velasco G (September 2002). [\\\"Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway\\\"](https://doi.org/10.1074%2Fjbc.M205797200). _The Journal of Biological Chemistry_. **277** (39): 36527â€“33\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1074/jbc.M205797200](https://doi.org/10.1074%2Fjbc.M205797200). [hdl](Hdl_\\\\(identifier\\\\) \\\"Hdl \\\\(identifier\\\\)\\\"):[10261/36487](https://hdl.handle.net/10261%2F36487). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12133838](https://pubmed.ncbi.nlm.nih.gov/12133838).\",\"description\":\"19. **^** GÃ³mez Del Pulgar T, De Ceballos ML, GuzmÃ¡n M, Velasco G (September 2002). [\\\"Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway\\\"](https://doi.org/10.1074%2Fjbc.M205797200). _The Journal of Biological Chemistry_. **277** (39): 36527â€“33\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1074/jbc.M205797200](https://doi.org/10.1074%2Fjbc.M205797200). [hdl](Hdl_\\\\(identifier\\\\) \\\"Hdl \\\\(identifier\\\\)\\\"):[10261/36487](https://hdl.handle.net/10261%2F36487). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12133838](https://pubmed.ncbi.nlm.nih.gov/12133838).\",\"url\":\"https://doi.org/10.1074%2Fjbc.M205797200\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"** Welch HC, Coadwell WJ, Stephens LR, Hawkins PT (July 2003). [\\\"Phosphoinositide 3-kinase-dependent activation of Rac\\\"](https://doi.org/10.1016%2Fs0014-5793%2803%2900454-x). _FEBS Letters_. **546** (1): 93â€“7\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2003FEBSL.546...93W](https://ui.adsabs.harvard.edu/abs/2003FEBSL.546...93W). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/s0014-5793(03)00454-x](https://doi.org/10.1016%2Fs0014-5793%2803%2900454-x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12829242](https://pubmed.ncbi.nlm.nih.gov/12829242).\",\"description\":\"20. **^** Welch HC, Coadwell WJ, Stephens LR, Hawkins PT (July 2003). [\\\"Phosphoinositide 3-kinase-dependent activation of Rac\\\"](https://doi.org/10.1016%2Fs0014-5793%2803%2900454-x). _FEBS Letters_. **546** (1): 93â€“7\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2003FEBSL.546...93W](https://ui.adsabs.harvard.edu/abs/2003FEBSL.546...93W). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/s0014-5793(03)00454-x](https://doi.org/10.1016%2Fs0014-5793%2803%2900454-x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12829242](https://pubmed.ncbi.nlm.nih.gov/12829242).\",\"url\":\"https://doi.org/10.1016%2Fs0014-5793%2803%2900454-x\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"** Jaffe AB, Hall A (2005). \\\"Rho GTPases: biochemistry and biology\\\". _Annual Review of Cell and Developmental Biology_. **21** : 247â€“69\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1146/annurev.cellbio.21.020604.150721](https://doi.org/10.1146%2Fannurev.cellbio.21.020604.150721). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16212495](https://pubmed.ncbi.nlm.nih.gov/16212495).\",\"description\":\"21. **^** Jaffe AB, Hall A (2005). \\\"Rho GTPases: biochemistry and biology\\\". _Annual Review of Cell and Developmental Biology_. **21** : 247â€“69\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1146/annurev.cellbio.21.020604.150721](https://doi.org/10.1146%2Fannurev.cellbio.21.020604.150721). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16212495](https://pubmed.ncbi.nlm.nih.gov/16212495).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"_**a**_ _**b**_ Bleeker FE, Lamba S, Zanon C, Molenaar RJ, Hulsebos TJ, Troost D, et al. (September 2014). [\\\"Mutational profiling of kinases in glioblastoma\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192443). _BMC Cancer_. **14** 718\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1186/1471-2407-14-718](https://doi.org/10.1186%2F1471-2407-14-718). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4192443](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192443). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25256166](https://pubmed.ncbi.nlm.nih.gov/25256166).\",\"description\":\"22. ^ _**a**_ _**b**_ Bleeker FE, Lamba S, Zanon C, Molenaar RJ, Hulsebos TJ, Troost D, et al. (September 2014). [\\\"Mutational profiling of kinases in glioblastoma\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192443). _BMC Cancer_. **14** 718\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1186/1471-2407-14-718](https://doi.org/10.1186%2F1471-2407-14-718). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4192443](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192443). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25256166](https://pubmed.ncbi.nlm.nih.gov/25256166).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192443\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"** Bleeker FE, Molenaar RJ, Leenstra S (May 2012). [\\\"Recent advances in the molecular understanding of glioblastoma\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337398). _Journal of Neuro-Oncology_. **108** (1): 11â€“27\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s11060-011-0793-0](https://doi.org/10.1007%2Fs11060-011-0793-0). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3337398](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337398). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22270850](https://pubmed.ncbi.nlm.nih.gov/22270850).\",\"description\":\"23. **^** Bleeker FE, Molenaar RJ, Leenstra S (May 2012). [\\\"Recent advances in the molecular understanding of glioblastoma\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337398). _Journal of Neuro-Oncology_. **108** (1): 11â€“27\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1007/s11060-011-0793-0](https://doi.org/10.1007%2Fs11060-011-0793-0). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3337398](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337398). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22270850](https://pubmed.ncbi.nlm.nih.gov/22270850).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337398\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"** Man HY, Wang Q, Lu WY, Ju W, Ahmadian G, Liu L, et al. (May 2003). [\\\"Activation of PI3-kinase is required for AMPA receptor insertion during LTP of mEPSCs in cultured hippocampal neurons\\\"](https://doi.org/10.1016%2FS0896-6273%2803%2900228-9). _Neuron_. **38** (4): 611â€“24\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/S0896-6273(03)00228-9](https://doi.org/10.1016%2FS0896-6273%2803%2900228-9). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12765612](https://pubmed.ncbi.nlm.nih.gov/12765612).\",\"description\":\"24. **^** Man HY, Wang Q, Lu WY, Ju W, Ahmadian G, Liu L, et al. (May 2003). [\\\"Activation of PI3-kinase is required for AMPA receptor insertion during LTP of mEPSCs in cultured hippocampal neurons\\\"](https://doi.org/10.1016%2FS0896-6273%2803%2900228-9). _Neuron_. **38** (4): 611â€“24\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/S0896-6273(03)00228-9](https://doi.org/10.1016%2FS0896-6273%2803%2900228-9). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12765612](https://pubmed.ncbi.nlm.nih.gov/12765612).\",\"url\":\"https://doi.org/10.1016%2FS0896-6273%2803%2900228-9\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"** Joyal JL, Burks DJ, Pons S, Matter WF, Vlahos CJ, White MF, Sacks DB (November 1997). [\\\"Calmodulin activates phosphatidylinositol 3-kinase\\\"](https://doi.org/10.1074%2Fjbc.272.45.28183). _The Journal of Biological Chemistry_. **272** (45): 28183â€“6\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1074/jbc.272.45.28183](https://doi.org/10.1074%2Fjbc.272.45.28183). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [9353264](https://pubmed.ncbi.nlm.nih.gov/9353264).\",\"description\":\"25. **^** Joyal JL, Burks DJ, Pons S, Matter WF, Vlahos CJ, White MF, Sacks DB (November 1997). [\\\"Calmodulin activates phosphatidylinositol 3-kinase\\\"](https://doi.org/10.1074%2Fjbc.272.45.28183). _The Journal of Biological Chemistry_. **272** (45): 28183â€“6\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1074/jbc.272.45.28183](https://doi.org/10.1074%2Fjbc.272.45.28183). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [9353264](https://pubmed.ncbi.nlm.nih.gov/9353264).\",\"url\":\"https://doi.org/10.1074%2Fjbc.272.45.28183\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"** Sanna PP, Cammalleri M, Berton F, Simpson C, Lutjens R, Bloom FE, Francesconi W (May 2002). [\\\"Phosphatidylinositol 3-kinase is required for the expression but not for the induction or the maintenance of long-term potentiation in the hippocampal CA1 region\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6758361). _The Journal of Neuroscience_. **22** (9): 3359â€“65\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1523/JNEUROSCI.22-09-03359.2002](https://doi.org/10.1523%2FJNEUROSCI.22-09-03359.2002). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6758361](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6758361). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11978812](https://pubmed.ncbi.nlm.nih.gov/11978812).\",\"description\":\"26. **^** Sanna PP, Cammalleri M, Berton F, Simpson C, Lutjens R, Bloom FE, Francesconi W (May 2002). [\\\"Phosphatidylinositol 3-kinase is required for the expression but not for the induction or the maintenance of long-term potentiation in the hippocampal CA1 region\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6758361). _The Journal of Neuroscience_. **22** (9): 3359â€“65\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1523/JNEUROSCI.22-09-03359.2002](https://doi.org/10.1523%2FJNEUROSCI.22-09-03359.2002). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6758361](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6758361). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11978812](https://pubmed.ncbi.nlm.nih.gov/11978812).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6758361\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"** Karpova A, Sanna PP, Behnisch T (February 2006). \\\"Involvement of multiple phosphatidylinositol 3-kinase-dependent pathways in the persistence of late-phase long term potentiation expression\\\". _Neuroscience_. **137** (3): 833â€“41\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.neuroscience.2005.10.012](https://doi.org/10.1016%2Fj.neuroscience.2005.10.012). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16326012](https://pubmed.ncbi.nlm.nih.gov/16326012). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [38232127](https://api.semanticscholar.org/CorpusID:38232127).\",\"description\":\"27. **^** Karpova A, Sanna PP, Behnisch T (February 2006). \\\"Involvement of multiple phosphatidylinositol 3-kinase-dependent pathways in the persistence of late-phase long term potentiation expression\\\". _Neuroscience_. **137** (3): 833â€“41\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.neuroscience.2005.10.012](https://doi.org/10.1016%2Fj.neuroscience.2005.10.012). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16326012](https://pubmed.ncbi.nlm.nih.gov/16326012). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [38232127](https://api.semanticscholar.org/CorpusID:38232127).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"** Opazo P, Watabe AM, Grant SG, O'Dell TJ (May 2003). [\\\"Phosphatidylinositol 3-kinase regulates the induction of long-term potentiation through extracellular signal-related kinase-independent mechanisms\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742185). _The Journal of Neuroscience_. **23** (9): 3679â€“88\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1523/JNEUROSCI.23-09-03679.2003](https://doi.org/10.1523%2FJNEUROSCI.23-09-03679.2003). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6742185](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742185). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12736339](https://pubmed.ncbi.nlm.nih.gov/12736339).\",\"description\":\"28. **^** Opazo P, Watabe AM, Grant SG, O'Dell TJ (May 2003). [\\\"Phosphatidylinositol 3-kinase regulates the induction of long-term potentiation through extracellular signal-related kinase-independent mechanisms\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742185). _The Journal of Neuroscience_. **23** (9): 3679â€“88\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1523/JNEUROSCI.23-09-03679.2003](https://doi.org/10.1523%2FJNEUROSCI.23-09-03679.2003). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6742185](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742185). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12736339](https://pubmed.ncbi.nlm.nih.gov/12736339).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742185\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"_**a**_ _**b**_ Yang PC, Yang CH, Huang CC, Hsu KS (February 2008). [\\\"Phosphatidylinositol 3-kinase activation is required for stress protocol-induced modification of hippocampal synaptic plasticity\\\"](https://doi.org/10.1074%2Fjbc.M706954200). _The Journal of Biological Chemistry_. **283** (5): 2631â€“43\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1074/jbc.M706954200](https://doi.org/10.1074%2Fjbc.M706954200). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18057005](https://pubmed.ncbi.nlm.nih.gov/18057005).\",\"description\":\"29. ^ _**a**_ _**b**_ Yang PC, Yang CH, Huang CC, Hsu KS (February 2008). [\\\"Phosphatidylinositol 3-kinase activation is required for stress protocol-induced modification of hippocampal synaptic plasticity\\\"](https://doi.org/10.1074%2Fjbc.M706954200). _The Journal of Biological Chemistry_. **283** (5): 2631â€“43\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1074/jbc.M706954200](https://doi.org/10.1074%2Fjbc.M706954200). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18057005](https://pubmed.ncbi.nlm.nih.gov/18057005).\",\"url\":\"https://doi.org/10.1074%2Fjbc.M706954200\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"** Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, et al. (March 2007). [\\\"LTP inhibits LTD in the hippocampus via regulation of GSK3beta\\\"](http://www.hal.inserm.fr/inserm-00776885). _Neuron_. **53** (5): 703â€“17\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.neuron.2007.01.029](https://doi.org/10.1016%2Fj.neuron.2007.01.029). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17329210](https://pubmed.ncbi.nlm.nih.gov/17329210). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [6903401](https://api.semanticscholar.org/CorpusID:6903401).\",\"description\":\"30. **^** Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, et al. (March 2007). [\\\"LTP inhibits LTD in the hippocampus via regulation of GSK3beta\\\"](http://www.hal.inserm.fr/inserm-00776885). _Neuron_. **53** (5): 703â€“17\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.neuron.2007.01.029](https://doi.org/10.1016%2Fj.neuron.2007.01.029). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17329210](https://pubmed.ncbi.nlm.nih.gov/17329210). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [6903401](https://api.semanticscholar.org/CorpusID:6903401).\",\"url\":\"http://www.hal.inserm.fr/inserm-00776885\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"** Toker A, Cantley LC (June 1997). [\\\"Signalling through the lipid products of phosphoinositide-3-OH kinase\\\"](https://doi.org/10.1038%2F42648). _Nature_. **387** (6634): 673â€“6\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[1997Natur.387..673T](https://ui.adsabs.harvard.edu/abs/1997Natur.387..673T). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/42648](https://doi.org/10.1038%2F42648). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [9192891](https://pubmed.ncbi.nlm.nih.gov/9192891). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [4347728](https://api.semanticscholar.org/CorpusID:4347728).\",\"description\":\"31. **^** Toker A, Cantley LC (June 1997). [\\\"Signalling through the lipid products of phosphoinositide-3-OH kinase\\\"](https://doi.org/10.1038%2F42648). _Nature_. **387** (6634): 673â€“6\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[1997Natur.387..673T](https://ui.adsabs.harvard.edu/abs/1997Natur.387..673T). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/42648](https://doi.org/10.1038%2F42648). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [9192891](https://pubmed.ncbi.nlm.nih.gov/9192891). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [4347728](https://api.semanticscholar.org/CorpusID:4347728).\",\"url\":\"https://doi.org/10.1038%2F42648\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"** Cammalleri M, LÃ¼tjens R, Berton F, King AR, Simpson C, Francesconi W, Sanna PP (November 2003). [\\\"Time-restricted role for dendritic activation of the mTOR-p70S6K pathway in the induction of late-phase long-term potentiation in the CA1\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC283598). _Proceedings of the National Academy of Sciences of the United States of America_. **100** (24): 14368â€“73\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2003PNAS..10014368C](https://ui.adsabs.harvard.edu/abs/2003PNAS..10014368C). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1073/pnas.2336098100](https://doi.org/10.1073%2Fpnas.2336098100). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [283598](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC283598). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [14623952](https://pubmed.ncbi.nlm.nih.gov/14623952).\",\"description\":\"32. **^** Cammalleri M, LÃ¼tjens R, Berton F, King AR, Simpson C, Francesconi W, Sanna PP (November 2003). [\\\"Time-restricted role for dendritic activation of the mTOR-p70S6K pathway in the induction of late-phase long-term potentiation in the CA1\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC283598). _Proceedings of the National Academy of Sciences of the United States of America_. **100** (24): 14368â€“73\\\\. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2003PNAS..10014368C](https://ui.adsabs.harvard.edu/abs/2003PNAS..10014368C). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1073/pnas.2336098100](https://doi.org/10.1073%2Fpnas.2336098100). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [283598](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC283598). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [14623952](https://pubmed.ncbi.nlm.nih.gov/14623952).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC283598\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"** Kumar DT, Doss CG (2016-01-01). _Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain: A Molecular Docking and Molecular Dynamics Approach_. Vol. 102\\\\. pp. 267â€“97\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/bs.apcsb.2015.09.008](https://doi.org/10.1016%2Fbs.apcsb.2015.09.008). [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9780128047958. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26827608](https://pubmed.ncbi.nlm.nih.gov/26827608). `{{cite book}}`: `|journal=` ignored (help)\",\"description\":\"33. **^** Kumar DT, Doss CG (2016-01-01). _Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain: A Molecular Docking and Molecular Dynamics Approach_. Vol. 102\\\\. pp. 267â€“97\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/bs.apcsb.2015.09.008](https://doi.org/10.1016%2Fbs.apcsb.2015.09.008). [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 9780128047958. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26827608](https://pubmed.ncbi.nlm.nih.gov/26827608). `{{cite book}}`: `|journal=` ignored (help)\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"** Sudhakar N, Priya Doss CG, Thirumal Kumar D, Chakraborty C, Anand K, Suresh M (2016-01-02). \\\"Deciphering the impact of somatic mutations in exon 20 and exon 9 of PIK3CA gene in breast tumors among Indian women through molecular dynamics approach\\\". _Journal of Biomolecular Structure \u0026 Dynamics_. **34** (1): 29â€“41\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1080/07391102.2015.1007483](https://doi.org/10.1080%2F07391102.2015.1007483). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25679319](https://pubmed.ncbi.nlm.nih.gov/25679319). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [205575161](https://api.semanticscholar.org/CorpusID:205575161).\",\"description\":\"34. **^** Sudhakar N, Priya Doss CG, Thirumal Kumar D, Chakraborty C, Anand K, Suresh M (2016-01-02). \\\"Deciphering the impact of somatic mutations in exon 20 and exon 9 of PIK3CA gene in breast tumors among Indian women through molecular dynamics approach\\\". _Journal of Biomolecular Structure \u0026 Dynamics_. **34** (1): 29â€“41\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1080/07391102.2015.1007483](https://doi.org/10.1080%2F07391102.2015.1007483). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25679319](https://pubmed.ncbi.nlm.nih.gov/25679319). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [205575161](https://api.semanticscholar.org/CorpusID:205575161).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"** Malone T, SchÃ¤fer L, Simon N, Heavey S, Cuffe S, Finn S, et al. (March 2020). [\\\"Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer\\\"](https://discovery.ucl.ac.uk/id/eprint/10088376/1/1-s2.0-S0163725819302062-main.pdf) (PDF). _Pharmacology \u0026 Therapeutics_. **207** 107454\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.pharmthera.2019.107454](https://doi.org/10.1016%2Fj.pharmthera.2019.107454). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [31836451](https://pubmed.ncbi.nlm.nih.gov/31836451). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [209357486](https://api.semanticscholar.org/CorpusID:209357486).\",\"description\":\"35. **^** Malone T, SchÃ¤fer L, Simon N, Heavey S, Cuffe S, Finn S, et al. (March 2020). [\\\"Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer\\\"](https://discovery.ucl.ac.uk/id/eprint/10088376/1/1-s2.0-S0163725819302062-main.pdf) (PDF). _Pharmacology \u0026 Therapeutics_. **207** 107454\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.pharmthera.2019.107454](https://doi.org/10.1016%2Fj.pharmthera.2019.107454). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [31836451](https://pubmed.ncbi.nlm.nih.gov/31836451). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [209357486](https://api.semanticscholar.org/CorpusID:209357486).\",\"url\":\"https://discovery.ucl.ac.uk/id/eprint/10088376/1/1-s2.0-S0163725819302062-main.pdf\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"** Luszczak S, Kumar C, Sathyadevan VK, Simpson BS, Gately KA, Whitaker HC, Heavey S (2020). [\\\"PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992635). _Signal Transduction and Targeted Therapy_. **5** 7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/s41392-020-0109-y](https://doi.org/10.1038%2Fs41392-020-0109-y). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6992635](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992635). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32025342](https://pubmed.ncbi.nlm.nih.gov/32025342).\",\"description\":\"36. **^** Luszczak S, Kumar C, Sathyadevan VK, Simpson BS, Gately KA, Whitaker HC, Heavey S (2020). [\\\"PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992635). _Signal Transduction and Targeted Therapy_. **5** 7\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/s41392-020-0109-y](https://doi.org/10.1038%2Fs41392-020-0109-y). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [6992635](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992635). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [32025342](https://pubmed.ncbi.nlm.nih.gov/32025342).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992635\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"** Heavey S, Dowling P, Moore G, Barr MP, Kelly N, Maher SG, et al. (January 2018). [\\\"Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786033). _Scientific Reports_. **8** (1) 1652. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2018NatSR...8.1652H](https://ui.adsabs.harvard.edu/abs/2018NatSR...8.1652H). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/s41598-018-19688-1](https://doi.org/10.1038%2Fs41598-018-19688-1). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5786033](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786033). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29374181](https://pubmed.ncbi.nlm.nih.gov/29374181).\",\"description\":\"37. **^** Heavey S, Dowling P, Moore G, Barr MP, Kelly N, Maher SG, et al. (January 2018). [\\\"Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786033). _Scientific Reports_. **8** (1) 1652. [Bibcode](Bibcode_\\\\(identifier\\\\) \\\"Bibcode \\\\(identifier\\\\)\\\"):[2018NatSR...8.1652H](https://ui.adsabs.harvard.edu/abs/2018NatSR...8.1652H). [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/s41598-018-19688-1](https://doi.org/10.1038%2Fs41598-018-19688-1). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [5786033](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786033). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [29374181](https://pubmed.ncbi.nlm.nih.gov/29374181).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786033\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"** Heavey S, Godwin P, Baird AM, Barr MP, Umezawa K, Cuffe S, et al. (October 2014). [\\\"Strategic targeting of the PI3K-NFÎºB axis in cisplatin-resistant NSCLC\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130730). _Cancer Biology \u0026 Therapy_. **15** (10): 1367â€“77\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4161/cbt.29841](https://doi.org/10.4161%2Fcbt.29841). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4130730](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130730). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25025901](https://pubmed.ncbi.nlm.nih.gov/25025901).\",\"description\":\"38. **^** Heavey S, Godwin P, Baird AM, Barr MP, Umezawa K, Cuffe S, et al. (October 2014). [\\\"Strategic targeting of the PI3K-NFÎºB axis in cisplatin-resistant NSCLC\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130730). _Cancer Biology \u0026 Therapy_. **15** (10): 1367â€“77\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4161/cbt.29841](https://doi.org/10.4161%2Fcbt.29841). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4130730](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130730). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25025901](https://pubmed.ncbi.nlm.nih.gov/25025901).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130730\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"** Heavey S, O'Byrne KJ, Gately K (April 2014). \\\"Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC\\\". _Cancer Treatment Reviews_. **40** (3): 445â€“56\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ctrv.2013.08.006](https://doi.org/10.1016%2Fj.ctrv.2013.08.006). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24055012](https://pubmed.ncbi.nlm.nih.gov/24055012).\",\"description\":\"39. **^** Heavey S, O'Byrne KJ, Gately K (April 2014). \\\"Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC\\\". _Cancer Treatment Reviews_. **40** (3): 445â€“56\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.ctrv.2013.08.006](https://doi.org/10.1016%2Fj.ctrv.2013.08.006). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24055012](https://pubmed.ncbi.nlm.nih.gov/24055012).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"}],\"images\":[],\"fixedIssues\":[{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"capable of phosphorylating the 3 position hydroxyl group of the inositol ring of phosphatidylinositol (PtdIns).[2]\",\"explanation\":\"Reference [2] discusses the structure of myo-inositol but does not describe the enzymatic activity or mechanism of PI3Ks in phosphorylating phosphatidylinositol. This misattributes the source, potentially undermining verifiability of the core definitional claim about PI3K function.\",\"fixedText\":\"Replace citation [2] with a source that directly supports the phosphorylation mechanism, such as [](https://pmc.ncbi.nlm.nih.gov/articles/PMC3414724/), which states: \\\"Phosphoinositide 3-kinases (PI3K) are a family of enzymes that selectively phosphorylate the D3 hydroxyl group of the inositol head group of phosphoinositide.\\\"\",\"evidenceSource\":\"[2] or [](https://web.archive.org/web/20110806104525/http://www.chem.qmul.ac.uk/iupac/cyclitol/myo.html)\"},{\"criticality\":\"Critical\",\"issueType\":\"Figures/Tables/Data Presentation\",\"problematicText\":\"The table lists EC numbers only for PIK3CA (2.7.1.153), PIK3C2A (2.7.1.154), and PIK3C3 (2.7.1.137), leaving blanks for other class I catalytic subunits (PIK3CB, PIK3CG, PIK3CD) and class II (PIK3C2B, PIK3C2G).\",\"explanation\":\"All class I catalytic subunits (PIK3CA, PIK3CB, PIK3CD, PIK3CG) share EC 2.7.1.153. All class II (PIK3C2A, PIK3C2B, PIK3C2G) share EC 2.7.1.154. Blanks imply absence of EC numbers, which is inaccurate and misleads on enzymatic classification.\",\"fixedText\":\"Add EC 2.7.1.153 to PIK3CB, PIK3CG, PIK3CD rows; add EC 2.7.1.154 to PIK3C2B and PIK3C2G rows in the table.\",\"evidenceSource\":\"UniProt entries for PIK3CB (Q9H04), PIK3CG (P48736), PIK3CD (O00358), PIK3C2B (O00750), PIK3C2G (O75747); BRENDA enzyme database.\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"PI3Ks are phosphorylated upon [NMDA receptor](NMDA_receptor \\\"NMDA receptor\\\")-dependent [CaMKII](CaMKII \\\"CaMKII\\\") activity,[25]\\\"\",\"explanation\":\"Reference [25] (Joyal et al., 1997) discusses calmodulin activation of PI3K but does not support the specific claim of PI3Ks being phosphorylated by NMDA-dependent CaMKII activity. While there is general evidence for PI3K activation via NMDA/CaMKII pathways, the citation does not match the claim, leading to unverifiable information.\",\"fixedText\":\"Rephrase to \\\"PI3K is activated downstream of NMDA receptor-dependent CaMKII activity\\\" and cite an appropriate source such as Man et al. (2003) [24] or a new reference; retain [25] if rephrasing to calmodulin involvement.\",\"evidenceSource\":\"[25]\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"The [PI3K pathway](PI3K/AKT/mTOR_pathway \\\"PI3K/AKT/mTOR pathway\\\") also recruits many other proteins downstream, including [mTOR](MTOR \\\"MTOR\\\"),[29] [GSK3Î²](GSK3%CE%B2 \\\"GSK3Î²\\\"),[30] and [PSD-95](PSD-95 \\\"PSD-95\\\").[29]\\\"\",\"explanation\":\"Reference [29] (Yang et al., 2008) focuses on PI3K activation in stress-induced hippocampal synaptic plasticity but does not discuss recruitment or role of mTOR or PSD-95 specifically. The dual citation to [29] for unrelated proteins creates inaccuracy in supporting evidence.\",\"fixedText\":\"Remove [29] for mTOR and PSD-95 or replace with appropriate citations (e.g., for mTOR in LTP, use [32]; for PSD-95, find specific source). Retain [30] for GSK3Î² as it matches.\",\"evidenceSource\":\"[29]\"},{\"criticality\":\"Critical\",\"issueType\":\"Internal Contradiction\",\"problematicText\":\"\\\"PI3Ks interact with the [insulin receptor substrate](Insulin_receptor_substrate \\\"Insulin receptor substrate\\\") (IRS) to regulate glucose uptake through a series of phosphorylation events.\\\"\",\"explanation\":\"This sentence appears at the end of the \\\"Learning and memory\\\" subsection but describes insulin signaling, which duplicates content from the main \\\"Function\\\" paragraph and does not relate to learning/memory or LTP. It disrupts subsection coherence and creates redundancy with the article structure.\",\"fixedText\":\"Remove the sentence from \\\"Learning and memory\\\" as it duplicates earlier content; no new citation needed.\",\"evidenceSource\":\"Article structure (Function covers insulin signaling broadly)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"\\\"PI3K is also involved in interleukin signalling (IL4) \\\"\",\"explanation\":\"The sentence is incomplete (trailing space, no period, \\\"IL4\\\" should be \\\"IL-4\\\"), lacks a citation, and abruptly ends without elaboration. This creates a knowledge gap on PI3K's role in IL-4 signaling, which is relevant to immune functions mentioned earlier.\",\"fixedText\":\"Complete to \\\"PI3K is also involved in interleukin-4 (IL-4) signaling in immune cells\\\" and add a citation, e.g., to Okkenhaug (2013) [13] or a new source.\",\"evidenceSource\":\"No citation\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"It has been shown that malignant B cells maintain a \\\"tonic\\\" activity of PI3K/Akt axis via upregulation of an adaptor protein GAB1, and this also allows B cells to survive targeted therapy with BCR inhibitors. \\\"\",\"explanation\":\"The claim is factually supported by literature but lacks any citation, violating verifiability. As a specific mechanism in cancer, unsourced status makes it critically unsupported.\",\"fixedText\":\"Add citation immediately after the claim, e.g., to Chen et al. (2021) or similar recent review on GAB1 in B-cell malignancies.\",\"evidenceSource\":\"No citation\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"however, it is unclear whether this has any role _in vivo_.\",\"explanation\":\"The claim that the serine/threonine kinase activity of PI3Ks has no known role in vivo is outdated. A 2025 study demonstrates that PI3KÎ²'s protein kinase activity promotes tumor growth in vivo by enhancing protein O-GlcNAcylation and acetyl-CoA production, clarifying its physiological relevance in cancer.\",\"fixedText\":\"Revise to: \\\"; recent studies have shown that this activity plays a role in vivo, for example, in PI3KÎ²-mediated tumor progression.\\\"\",\"evidenceSource\":\"[](https://www.cell.com/molecular-cell/fulltext/S1097-2765(25)00186-8)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"The entire section.\",\"explanation\":\"The section makes factual claims about PI3K protein kinase activity without any citations, rendering it unsupported and potentially unverifiable. Given the specialized nature of the claim, sourcing is essential for verifiability.\",\"fixedText\":\"Add citations to reliable sources confirming in vitro activity and the recent in vivo role.\",\"evidenceSource\":\"No existing ref supports this; new source needed: [](https://pmc.ncbi.nlm.nih.gov/articles/PMC3601961/)\"},{\"criticality\":\"Non-Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"N/A\",\"explanation\":\"The section lacks details on which PI3Ks exhibit this activity (e.g., class IA, PI3KÎ²) and specific in vivo contexts (e.g., tumor growth via O-GlcNAcylation), which are recent developments as of 2025 providing historical and mechanistic context.\",\"fixedText\":\"Incorporate brief mention of specific examples and mechanisms to fill the knowledge gap without duplicating other sections like \\\"Function\\\" or \\\"Inhibition\\\".\",\"evidenceSource\":\"[](https://www.cell.com/molecular-cell/fulltext/S1097-2765(25)00186-8)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"As of January 2019, three PI3K inhibitors are approved by the [FDA](Food_and_Drug_Administration \\\"Food and Drug Administration\\\") for routine clinical use in humans: the PIK3CD inhibitor [idelalisib](Idelalisib \\\"Idelalisib\\\") (July 2014, [NDA 206545](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process\u0026ApplNo=206545)), the dual PIK3CA and PIK3CD inhibitor [copanlisib](Copanlisib \\\"Copanlisib\\\") (September 2017, [NDA 209936](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process\u0026ApplNo=209936)), and the dual PIK3CD and PIK3CG inhibitor [duvelisib](Duvelisib \\\"Duvelisib\\\") (September 2018, [NDA 211155](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process\u0026ApplNo=211155)).\",\"explanation\":\"The list is outdated as of the current date (October 25, 2025). Alpelisib was approved in May 2019 (after January 2019). Copanlisib's approval was withdrawn in March 2024 due to safety concerns and lack of confirmatory trial data. Inavolisib was approved in October 2024. Duvelisib and idelalisib remain approved but with narrowed indications (follicular lymphoma indications withdrawn). The section must reflect current FDA approvals for accuracy in describing therapeutic use, primarily in cancer contexts.\",\"fixedText\":\"Update to: \\\"As of October 2025, four PI3K inhibitors are approved by the FDA for routine clinical use in humans with cancers: the PI3KÎ´ inhibitor idelalisib (approved July 2014 for relapsed CLL), the PI3KÎ± inhibitor alpelisib (approved May 2019 for PIK3CA-mutated HR+/HER2- breast cancer), the dual PI3KÎ´/Î³ inhibitor duvelisib (approved September 2018 for relapsed CLL/SLL), and the PI3KÎ± inhibitor inavolisib (approved October 2024 for PIK3CA-mutated, endocrine-resistant HR+/HER2- breast cancer).\\\" Include relevant NDA links where available and cite FDA sources. Remove copanlisib.\",\"evidenceSource\":\"[](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alpelisib-metastatic-breast-cancer); [](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive); [](https://www.federalregister.gov/documents/2024/03/18/2024-05619/bayer-healthcare-pharmaceuticals-inc-withdrawal-of-approval-of-new-drug-application-for-aliqopa)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"\",\"explanation\":\"The section lacks mention of alpelisib and inavolisib, which are key developments in PI3K-targeted cancer therapeutics since the original 2019 cutoff. This creates a knowledge gap on recent approvals and their specificity (both PI3KÎ± for breast cancer), impacting completeness for a Wikipedia article on PI3K inhibitors as therapeutics.\",\"fixedText\":\"Add alpelisib and inavolisib to the list of approved inhibitors with approval dates, indications, and isoform specificity, citing FDA approval announcements.\",\"evidenceSource\":\"[](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alpelisib-metastatic-breast-cancer); [](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive)\"}],\"slug\":\"Phosphoinositide_3-kinase\",\"title\":\"Phosphoinositide 3-kinase\",\"content\":\"$1f\",\"description\":\"Phosphoinositide 3-kinase\\n\\nPhosphoinositide 3-kinases (PI3Ks), also called phosphatidylinositol 3-kinases, are a family of enzymes involved in cellular functions such as cell growth, proliferation,...\",\"metadata\":{\"categories\":[\"PI3K\",\"Phosphatidylinositol 3-kinase\",\"PI 3-kinase\",\"PI3-kinase\"],\"lastModified\":\"1761553160\",\"contentLength\":\"18404\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"55691\",\"recentViews\":\"55691\",\"dailyAvgViews\":1856.36669921875,\"qualityScore\":1,\"lastViewed\":\"1761885809\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761885809425,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Phosphoinositide_3-kinase\"],\"queryHash\":\"[\\\"page\\\",\\\"Phosphoinositide_3-kinase\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Phosphoinositide 3-kinase\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Phosphoinositide 3-kinases (PI3Ks), also called phosphatidylinositol 3-kinases, are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. PI3Ks are a family of related intracellular signal transducer enzymes capable of phosphorylating the 3 position hydroxyl group of the inositol ring of phosphatidylinositol (PtdIns). The pathway, with oncogene PIK3CA and...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"PI3K, Phosphatidylinositol 3-kinase, PI 3-kinase, PI3-kinase\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Phosphoinositide_3-kinase\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Phosphoinositide 3-kinase\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Phosphoinositide 3-kinases (PI3Ks), also called phosphatidylinositol 3-kinases, are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. PI3Ks are a family of related intracellular signal transducer enzymes capable of phosphorylating the 3 position hydroxyl group of the inositol ring of phosphatidylinositol (PtdIns). The pathway, with oncogene PIK3CA and...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Phosphoinositide_3-kinase\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Phosphoinositide 3-kinase\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:13.160Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Phosphoinositide 3-kinase\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Phosphoinositide 3-kinases (PI3Ks), also called phosphatidylinositol 3-kinases, are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. PI3Ks are a family of related intracellular signal transducer enzymes capable of phosphorylating the 3 position hydroxyl group of the inositol ring of phosphatidylinositol (PtdIns). The pathway, with oncogene PIK3CA and...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="YjMxMTJiOTEtNGU1My00NDE5LTljZTUtNmY0ODE3ODJlZDAy">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Phosphoinositide_3-kinase\"}]}]\n"])</script></body></html>